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ABSTRACT 
 
 
Metastatic breast cancer (MBC) is mainly responsible for breast cancer-related 
deaths worldwide. MBC is currently untreatable and has a 5-year survival rate of as low 
as 26% in patients. Hypoxia has been identified as a driving force for distant metastasis in 
breast cancer. Hypoxic response is primarily mediated by hypoxia-inducible factor, 
HIF1A which recruits chromatin remodelers and activates target genes directly or via 
downstream effector transcription factors. Several accessory molecules have also been 
implicated to be involved in the hypoxic response elicited by tumor cells. In this study, 
we focus on two such transcriptional regulators, SMARCE1 and BHLHE40, which play a 
pro-metastatic role in breast cancer progression in-vivo.  
 
SMARCE1 is a subunit of the chromatin remodeler complex SWI/SNF which 
causes nucleosome remodeling to facilitate expression of target genes. While aberrant 
activation of the chromatin-remodeling SWI/SNF complexes has been associated with 
cancer development and progression, the role of each subunit in tumor cells is poorly 
defined. This study characterizes the role of SMARCE1/BAF57 in regulating metastasis 
of breast cancer cells via the PTK2 pathway. SMARCE1-knockdown reduced lung 
metastasis of breast cancer cells and sensitized tumor cells to anoikis. In response to loss 
of attachment, SMARCE1 is shown to interact with and potentiate transcriptional activity 
of HIF1A, resulting in rapid PTK2 activation. Both HIF1A and PTK2 were indispensable 
for SMARCE1-mediated protection against anoikis by promoting activation of MAPK 
and AKT pathways while suppressing expression of pro-apoptotic BIM protein. 
Expression data analysis of a large cohort of human breast tumors revealed high 
expression of SMARCE1 or PTK2 is associated with poor prognosis and tumor relapse, 
and PTK2 expression is positively correlated with SMARCE1 expression in basal-like 
and luminal B subtypes of breast tumors.  
 
BHLHE40 is a validated target of HIF1A and its expression level is correlated 
with breast cancer grade and progression in patients. However, its exact role in the 
metastatic process is unclear. Here we reveal a novel role of BHLHE40 in regulating 
hypoxia-induced secretion of HBEGF to promote tumor cell growth and metastasis. 
BHLHE40 knockdown significantly reduced primary tumor growth and lung metastasis 
in orthotopic xenograft and experimental metastasis models of breast cancer. Gene 
expression analysis implicated a role of BHLHE40 in transcriptional activation of 
HBEGF, a heparin binding epidermal growth factor. Chromatin immunoprecipitation 
(ChIP) and co-immunoprecipitation (CoIP) assays revealed that BHLHE40 induces 
HBEGF transcription by blocking DNA binding of HDAC1 and HDAC2. Cell-based 
assays showed that HBEGF is secreted through exosomes and acts to promote cell 
survival and migration. Public database provided evidence linking high expression of 
BHLHE40 and HBEGF to poor prognosis of triple negative breast cancer. 
 
In summary, this study focused on two novel pro-metastatic mechanisms 
employed by HIF1A in breast cancer cells, which can be manipulated to target and 
modulate metastatic breast cancer therapeutically. While SMARCE1 plays an essential 
 vi 
role in breast cancer metastasis by protecting cells against anoikis through the 
HIF1A/PTK2 pathway, BHLHE40 increases metastatic potential by regulating exosomal 
secretion of HBEGF, which promotes breast cancer cell survival and migration. 
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CHAPTER 1.    INTRODUCTION 
 
 
Introduction 
 
 Metastasis is defined as the development of secondary malignant lesions distant 
from the primary site of origin. Breast cancer commonly metastasizes to the lung, liver, 
bones, and brain. Clinically metastatic breast cancer, known as stage IV (advanced stage) 
or recurrent cancer is responsible for 90% of metastasis-related deaths and currently does 
not have a cure [1]. Statistically, the National Cancer Institute predicts five-year relative 
breast cancer patient survival is as low as 26% in patients detected with stage-IV breast 
cancer as opposed to 99% in patients detected with stage-I breast cancer (Figure 1-1) [2]. 
Therefore, research has been strife [3] in this arena of metastatic breast cancer to find 
novel avenues for therapeutic intervention in patients. 
 
 Gene expression profiling has shown that clinical outcomes of patients diagnosed 
with breast cancer can be predicted using a signature gene array expression pattern [4, 5]. 
Specifically, breast tumors that occur by dysregulation of C-K-Ras proto-oncogene 
(KRAS) or HIF1A pathway show a higher proclivity for metastatic dissemination [6]. 
However, most researchers concede that metastasis proceeds in a sequential cascade of 
steps during which cells acquire specific characteristics for evading the immune system 
and enabling the cells to evade internal and environmental stressors[7]. Metastasis 
proceeds in a distinct cascade comprising the following sequence of steps: 
 
• Epithelial-Mesenchymal Transition (EMT), migration and invasion: tumor cells 
become locally invasive and migratory and invade the basement membrane 
• Intravasation: tumor cells enter the lymphatic and blood circulation 
• Circulation: tumor cells get transported to distant tissues via lymph and blood 
flow 
• Extravasation: tumor cells exit the blood circulation to distant secondary 
metastasis sites and may encounter dormancy 
• Distant metastasis: tumor cells overcome hostile stress in the distant stroma, 
reinitiate growth and from micro-metastasis that eventually form macro-
metastasis. 
 
 
Prerequisites for Metastasis 
 
Many genes and signaling pathways converge to achieve each of the above-listed 
steps, endowing cancer cells with abilities to challenge the defined organization and 
established homeostasis of target organ, as shown in Figure 1-2 [8]. While metastatic 
sites may be pre-disposed as outlined in the famous “seed and soil” concept proposed by 
Stephan Paget [9], prerequisites for the initiation of the metastatic cascade are numerous 
and contain key elements such as: the intrinsic tumor-initiating capacity, altered cell 
adhesions, loss of cell adhesion, motility, resistance to extracellular death signals and  
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Figure 1-1. Breast cancer metastasis.  
 
A. Breast cancer metastasis sites. Reprinted with permission from National Breast Cancer 
Foundation, Inc. (www.nationalbreastcancer.org/metastatic-breast-cancer) B. Breast 
cancer case statistics for year 2017. C. 5-year relative survival statistics for 2003-2013 
Reprinted with permission from SEER Cancer Stat Facts: Female Breast Cancer, 
National Cancer Institute, Bethesda, MD. 
(http://seer.cancer.gov/ststfacts/html/breast.html)  
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Figure 1-2. Metastatic cascade and signaling pathways involved.  
 
Reprinted with permission from Xin Jin, Targeting Breast Cancer Metastasis. Breast 
Cancer (Auckl), 2015; 9(Suppl 1): 23-34.  
 4 
eventual disruption of basement membrane[10]. Various intrinsic and extrinsic factors 
such as those listed in Figure 1-3 fueled by genomic and epigenetic instabilities are 
activated in each of the stages of the cascade enabling tumor cells to maximize metastatic 
potential [10]. Al-Hajj et al., first used fluorescence associated cell sorting experiments 
(FACS) to show that a CD44+/CD24-/low isolated cell population were more tumorigenic 
than other cell populations obtained from primary human xenograft tumors  [11]. Since 
that integral discovery, many researchers have focused on the identification of markers 
linked with tumor initiation capacity. The evidence of self-renewal of a small subset of 
tumor cells is minimal and yet to fully elucidated. However, this property is considered 
an essential pre-requisite to initiate metastasis [10]. Metastatic cells also lose intercellular 
adhesiveness molecularly explained by the loss of CDH1 (E-cadherin) and gain of CDH2 
(N-cadherin), leading to EMT. Following the loss of adhesion, metastatic cells gain 
motility via the upregulation of growth factor pathways. In MDA-MB-231, upregulation 
of epidermal growth factor receptors (EGFR) leads to increased invasiveness and cell 
motility, as shown in Matrigel-based invasion assays and scratch wound assays [12]. 
Evasion of apoptotic signals encountered by the metastatic cells which are generated by 
environmental stressors such as loss of adhesion, low nutrients, hypoxia and immune 
surveillance; is another vital prerequisite for metastatic cells [13]. Not only do metastatic 
cells evade immune surveillance but also manage to upregulate the secretion of a variety 
of matrix metalloproteases (MMP’s), which enable cells to invade the basement 
membrane, a key process required to form an overt metastatic lesion [14].   
 
Following intravasation, a whole new set of challenges and difficulty awaits a 
migratory cell. Hypoxia-activated matrix metalloproteases help in breaching the 
basement membrane as discussed above and cancer-associated fibroblasts have been 
implicated in the production of pro-metastatic cytokines like CXC motif chemokine 
ligand 12 (CXCL12), which facilitates intravasation, anoikis resistance and extravasation 
of cancer cells to distant organs [15, 16]. The pattern of colonization can be defined by 
the seed and soil concept proposed by Paget. Once extravasation has occurred, cancer 
cells may enter a state of dormancy, but eventually the cell must overcome this state in 
order to generate overt metastatic lesions [17]. Several mechanisms are involved in 
surmounting this dormancy, which are specific to the secondary organ being colonized. 
For example, production of colony stimulating factor (CSF1), tumor necrosis factor 
ligand (TNFSF11), and interleukins (IL6, IL8, IL11) are essential for successful 
colonization of tumor cells in bones [10]. 
 
 
Role of Tumor Hypoxia in Metastasis 
 
Tumor hypoxia is a dynamic condition that results in heterogeneity in tumor cell 
population and contributes to overall aggressiveness of the tumor [18]. Rapid utilization 
of oxygen and nutrients by the actively dividing tumor cells in solid tumors leads to the 
generation of hypoxia pockets and low nutrient availability, which is worsened by 
structurally and functionally abnormal vessels that form within solid tumors [19]. One 
way of measuring oxygen levels in tissue is by using electrodes to measure the partial  
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Figure 1-3. Cell intrinsic and extrinsic pressures that drive metastasis. 
 
Reprinted with permission from Joan Massague, Cancer Metastasis: Building a 
Framework. Cell, Volume 127, Issue 4, p679-659, November 2006. 
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pressure of oxygen (pO2). The median pO2 in healthy human breast tissue is 65mm of 
Hg, and by contrast breast cancer tissues have a median pO2 of 10mm of Hg [20]. pO2 of 
less than 10 mm Hg has been linked to increased metastasis in breast cancer [21]. One 
explanation offered for this phenomenon is that intratumoral hypoxia acts as a 
pathological stimulus, driving changes in gene expression leading to aberrant gene 
expression patterns contributing to a metastatic phenotype. In primary tumor cells, for 
instance, hypoxia upregulates the expression of CXC motif chemokine receptor (CXCR4) 
which leads to an increase in the migratory and invasive phenotype of MDA-MB-231 and 
MCF-7 cells lines [22]. Tumor cells have been noted to employ multiple strategies to 
overcome the hypoxia stress, becoming remarkably tolerant to hypoxia stress [23]. 
However, prolonged hypoxia or nutrient deprivation leads to necrotic cell death, which 
are found in solid breast tumors. Hypoxia of primary tumors have also been shown to 
trigger systemic release of molecules such as angiopoietin like protein 4 (ANGPTL4) and 
lysyl oxidase (LOX) which prime the metastatic niches for subsequent colonization of 
metastatic breast cancer cells [24, 25].  
 
Listed below are known mechanisms used by hypoxic stress to modulate 
metastatic potential: 
 
• Cytokine secretion – HIF1A regulate secretion of various cytokines which help 
promote primary tumor cell migration, angiogenesis, and immune evasion. HIF1A 
can activate vascular endothelial growth factor (VEGF) production to promote 
angiogenesis, and induces release of  C-C motif chemokine ligand 5 (CCL5) and 
CXCL12 to recruit myeloid cells which elicit an inflammatory response, and 
promote resistance to T-cell mediated death by increasing expression of 
programmed death-ligand-1 (CD274) on tumor cells [26].  
 
• Extracellular remodeling – Hypoxia can modulate the collagen present in the 
extracellular matrix via modulation of LOX family of proteins, they also 
upregulate secretion of matrix metalloproteinases that enable degradation of 
extracellular matrix (ECM) and aid migration of primary tumor cells [27].  
 
• Regulation of immune cell infiltration - HIF1A deficient mice show delays in 
myeloid cell infiltrations proving the importance of hypoxia in macrophage 
recruitment in tumors. These macrophages secrete growth factors and cytokines 
such as VEGF, platelet-derived growth factor (PDGF), interleukins, and  
transforming growth factor beta (TGFB) which may attract further macrophages, 
activate stromal cells and aid in the survival and proliferation of primary tumor 
cells [28, 29].  
 
• Metabolic adaptation – HIF1A mediated upregulation of glycolytic enzymes has 
been reported in several studies [30]. In order to maintain a high glycolytic rate, 
pyruvate is metabolized rapidly to lactate by HIF1A mediated upregulation of 
lactate dehydrogenate enzyme (LDHA) [31]. In conjunction with amplification of 
MYC proto-oncogene, HIF1A can also exploit glutamine metabolism which is 
also associated with increased aggressiveness of tumor cells [32]. HIF1A has also 
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been shown to engage tumor protein 53 (TP53) mediated gene expression in 
tumor cells experiencing chronic or prolonged hypoxic stress to overcome 
reactive oxygen species (ROS) stress [33, 34].  
 
• Anoikis resistance – Loss of attachment to basement membrane can cause loss of 
survival signals in tumor cells [35]. HIF1A has been shown to upregulate 
ANGPTL4 and EGFR pathway, while downregulating BCL2 interacting mediator 
of cell death (BCL2L11/BIM), BCL2 modifying factor (BMF), and integrin alpha 
subunit - ITGA5, leading to evasion of anoikis (apoptotic pathway initiated in 
detachment cells) [36-39].  
 
• Phenotypic plasticity (EMT/MET) – Rapid phenotypic change from epithelial 
to mesenchymal in the primary tumor site of the metastatic niche, plays a key role 
in metastasis [40]. Hypoxia has been known to promote EMT through direct 
HIF1A mediated transcriptional activation of Twist family basic helix-loop-helix 
transcription factor (TWIST) and zinc finger E-box binding protein (ZEB2), and 
also suppression of CDH1 [41]. 
 
Not only is hypoxia implicated in the increase of metastatic potential of breast 
cancer cells but this state has also been linked to chemo- and radio-resistance. This 
observation dates to 1953 when Grey et al., showed that sensitivity of tumor cells to X-
rays is about three times stronger when irradiated in an oxygenated medium as opposed 
to an anoxic medium [42]. Taken together these evidences suggest that hypoxia is an 
important multifaceted driver of metastasis, which leads to study of regulators in hypoxia 
pathway discussed below.  
 
 
Hypoxia Inducible Factor HIF1A Drives Metastasis 
 
Hypoxia is sensed by molecular dioxygenases such as prolyl dehydrogenases 
(PHD) in cells [43]. These oxidoreductase enzymes modify prolines in the oxygen-labile 
subunits of HIF in the presence of oxygen leading to an E3 dependent ubiquitination and 
degradation of HIF under average oxygen concentration [44]. In hypoxia, due to an 
absence of oxygen, PHD’s are inactive, leading to an increase in HIF activity [45]. HIF 
can, directly and indirectly, regulate cellular processes like cell cycle, cell growth, 
migration, invasion, autophagy, chemo-resistance, and anoikis-resistance, all of which 
may increase the metastatic potential of cancer cells [46]. HIF also regulates chromatin 
remodeling through epigenetic modifications, post-translational histone modifications 
and DNA methyltransferases [47].  
 
HIF are heterodimers comprising an oxygen-dependent subunit – HIF1-alpha 
(HIF1A/ HIF1α) and a constitutively expressed HIF1-beta (HIF1B/ HIF1β) subunits. It is 
the HIF1A subunit that contains the oxygen-mediated PHD modifiable proline residues. 
Under hypoxia, HIF1A is stabilized, and over 70 downstream direct transcriptional 
targets and approximately 1500 indirect downstream HIF targets have been identified till 
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date, all of which can help through the metastatic cascade of tumor cells [48] as shown in 
Figure 1-4.  
 
HIF1A promotes primary tumor growth and vascularization via direct 
upregulation of VEGF and CXCL12. sh-RNA mediated knockdown of HIF1A alone, 
may reduce lymph node metastasis, and osteolytic lesions. Conditional knockout of 
HIF1A in epithelial cells in MMTV-PyMT mice has been shown to decrease spontaneous 
lung metastases by ~50% [49]. During the metastatic cascade, HIF1A promotes EMT, 
migration, and invasion through the basement membrane by downregulation of CDH1 
and upregulation of SNAI1( Snail family Zinc finger transcription factor), SNAI2, 
TWIST, TCF3 (Transcription factor 3), HGF (Hepatocyte growth factor), ITGA5, 
ITGA6, MMP2 and MMP9 [50]. Intravasation and extravasation of tumor cells occur via 
loosened junctions amongst epithelial cells facilitated by the abnormal structure and 
function of tumor-associated blood vessels. VEGFA, VEGFC and (PDGFB), which are 
well documented angiogenic factors, are directly upregulated by HIF1A and help in intra-
tumoral vascularization, resulting in poorly constructed vasculature to facilitate 
intravasation or extravasation of tumor cells [51]. In addition, HIF1A mediated secretion 
of CXCL12 and CCL21(C-C motif chemokine ligand 21) that induce intravasation in 
breast cancer cells. Survival in lymphatic or blood circulation requires survival of breast 
cancer cells from anoikis, a form of cell death activated by loss of attachment. HIF1 has 
been shown to be activated upon loss of attachment and implicated in anoikis resistance 
via upregulating the EGFR- MAPK (mitogen activated protein kinase) pro-survival 
pathway [52]. Another target of HIF1A, L1 cell adhesion molecule (L1CAM) is a 
transmembrane protein which favorably mediates breast cancer cell and epithelial cell 
interactions aiding metastatic cells until they reach favorable metastatic niches to 
extravasate [50]. Specific cytokines have been shown to impart metastatic tropism to 
breast cancer cells. For example, HIF1A mediated expression of ANGPTL4 mediates 
tropism to lungs and CXCR4 expression confer tropism to bone [53, 54]. Upregulation of 
LOX and MMP’s favorably allow for the formation of overt metastases [55]. It is 
proposed that metastatic cells revert back to epithelial phenotype via PHD-mediated 
inactivation of HIF in non-hypoxic conditions thus relieving repression of CDH1 [56]. 
These studies have led to the identification of a variety of drugs that inhibit HIF1 activity 
in mice as shown in Figure 1-5 [57].  
 
Activation of HIF1A targets mentioned above could be by direct HIF1A-mediated 
transcriptional activation or indirectly via transcriptional factors induced by HIF1A. To 
bring about this activation, HIF can recruit chromatin modifying complexes such as 
SWI/SNF [58], ISWI [59] and several co-factors like CREB binding protein (CREBBP) 
and E1 binding protein 300 (EP300) [48]. Further study shows that regulation of 
downstream targets by HIF need a multiprotein complex which includes HIF1A, and the 
accessory transcription factor, p300/CREBBP [60, 61]. Sequence analysis of regions 
surrounding the functional hypoxia-responsive elements reveal motifs for binding of 
other transcription factors such as FOS (Fos proto-oncogene), CREB (cAMP responsive 
element binding protein), NYF (nuclear transcription factor), and E2F (Eukaryotic 
transcription factor), suggesting a functional interplay amongst DNA binding proteins, 
that may modify the hypoxic response [60]. However, this co-factor recruitment and  
 9 
 
 
Figure 1-4. Transcriptional targets of HIF. 
 
Seventy direct targets of HIF and the roles they orchestrate in the metastatic cascade. 
Reprinted with permission from Joaquin M Espinosa, Transcriptional Regulation by 
Hypoxia Inducible Factors. Crit Rev Biochem Mol Bio (HHS Author Manuscripts). 2014 
Jan-Feb; 49(1): 1-15. 
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Figure 1-5. HIF1A inhibitors modulate different aspects of the HIF1A activation 
pathway. 
 
Reprinted with permission fromWei Li, HIF-1α pathway: role, regulation and 
intervention for cancer therapy.Acta Pharm Sin B (Elsevier), 2015 Sep, 5(5): 378-389. 
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downstream pathway activation are cell context specific. Not only does the hypoxia 
response differ in different cell lines, a comparative study found the induction of HIF 
targets genes were higher in epithelial state compared to a mesenchymal state of the same 
cell line [48]. To compound its functional complexity, HIF1A may activate secondary 
downstream transcription factors like basic helix-loop-helix protein DEC1/ BHLHE40 
that help to further orchestrate the hypoxic response [62]. HIF1A, their direct targets, 
transcriptional co-regulators, and co-factors, can all contribute to every step of the 
metastatic cascade discussed above and impart resistance to immune attack via several 
HIF-dependent mechanisms during the metastatic process [29, 50]. Since the hypoxic 
response is one of the important drivers of metastasis, identifying the transcriptional co-
regulators of HIF1A may open doors to novel therapeutic interventions in patients.  
 
 
Screening for Transcriptional Regulators Involved in Metastasis of Breast Cancer 
Cells 
 
Transcription factors are favorably poised to rapidly activate or inactivate gene 
expression based on adjacent tumor cells and environmental cues, as shown in Figure 1-6 
[63]. Therefore, it comes as no surprise, that transcription factors are often deregulated by 
tumor cells to aid with tumor progression and metastasis. Transcription factors can 
upregulate or downregulate expression of specific downstream genes upon receiving 
signals from 19 key signal transduction pathways [63]. As discussed previously, 
development of cancer requires a multiplex reversible phenotype and several non-
Mendelian epigenetic alterations that may account for mosaic or tissue-specific gene 
expression. These features make transcription factors attractive targets for cancer therapy. 
Many researchers have now focused their efforts on studying how transcription factors 
affect genetic and epigenetic gene expression which aids tumor cell survival and 
proliferation, uncovering novel therapeutic targets for a more targeted cancer therapy 
[64].  
 
Many environmental cues including hypoxia have been shown to cause epigenetic 
modifications in solid tumors. The master hypoxia regulator HIF1A can cause both gene 
activation and repression imparting pro-survival ability, anti-apoptotic mechanisms, and 
resistance to radiation and chemotherapy in tumor cells, resulting in poor outcome in 
patients [65]. Several of these targets such as SNAI1 and TWIST are activated directly by 
HIF1A [50], but there are also a multitude of downstream targets whose activation is 
facilitated by other downstream transcription factors, epigenetic and chromatin 
remodelers, all of which are directly or indirectly influenced by HIF1A [48]. Many such 
downstream transcription factors and epigenetic modifiers such as histone methylases, 
demethylases, acetylases and chromatin remodelers, have been linked to an aggressive 
and malignant phenotype in patients. In this study, we dissect the role of such 
transcriptional modulators in metastasis of breast cancer.  
 
BHLHE40/DEC1 is a basic helix loop helix protein reported to be a 
transcriptional repressor involved in the regulation of genes associated with circadian 
rhythm, apoptosis and differentiation [66]. Immunohistochemical studies show that  
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Figure 1-6. Transcription factor activity. 
 
Simple flow diagram of transcriptional factor mediated pathway activation. Reprinted 
with permission from Daniel W Nerbert, Transcription factors and cancer: an overview. 
Toxicology (Elsevier), Volumes 181-182, 27 December 2002, Pages 131-141.  
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BHLHE40 is associated with tumor grade in patient-derived breast cancer tissues [67]. 
Overexpression of BHLHE40 can repress cell proliferation under normal conditions, but 
in a hostile environment like hypoxia or low nutrition, BHLHE40 upregulation can 
inhibit cell apoptosis and increase tumorigenicity [68]. Under hypoxic stress, BHLHE40, 
a direct target of HIF1A [36] is rapidly upregulated and has been shown to increase the 
invasiveness of breast cancer cell lines and impart metastatic potential [69]. BHLHE40 
has also been shown to increase breast cancer cell proliferation by increasing cyclin E 
levels [70]. BHLHE40 mediated suppression of clock (CLOCK/ BMAL1/2) genes 
activation, in turn, has been implicated in the modulation of drug toxicity [68]. Therefore, 
findings to date show that BHLHE40 plays an important role in the cancer progression 
and modulation of tumor response to chemotherapy [71]. However, how BHLHE40 
modulates these responses or tumor progression is unclear.  
 
HIF1A stimulates the expression of KDM6B [72], a lysine-specific histone 
demethylase that demethylates di- or tri- methylated lysine 27 of histone H3, causing 
gene expression. Since it is directly poised to activate genes in answer to up-stream cues, 
KDM6B has been investigated for its expression in various tumors. Specifically, KDM6B 
is known to increase invasiveness and promote epithelial-mesenchymal transition of 
breast cancer cells MDA-MB-231 cells via transcriptional upregulation of SNAI1 
expression [73]. EHMT2, another histone modifier modulated by hypoxia [74], is a 
histone lysine methyltransferase localized in euchromatin, which acts as a co-repressor 
along with partner transcription factors [75].  Increased expression of EHMT2 is 
observed in clinical cancer tissues and knockdown of EHMT2 in-vitro induces apoptotic 
cell death in various cancer cell lines [76].  
 
Finally, studies have focused intently on chromatin remodelers to elucidate their 
roles in hypoxia response modulation, cancer development and disease progression. 
Chromatin may assume a state as either euchromatin, containing loosely bound actively 
transcribed genes; or as heterochromatin, consisting of compact chromatin associated 
with silent genes [77]. Changes in chromatin structure is required for most cellular 
processes. Cells, therefore, have strategies in place for relaxing or tightening chromatin 
based on cellular cues or requirements. One such mechanism is using ATP-mediated 
chromatin remodelers. The well-characterized SWI/SNF (Switch/Sucrose 
Nonfermentable Complex) is a chromatin remodeler involved in hypoxia response [58]. 
SWI/SNF complex is evolutionarily conserved multi-subunit complex, containing the 
catalytic subunits with ATPase activity (SMARCA2/BRM or SMARCA4/BRG1) and 
other accessory subunits. Presence of SMARCA4 and SMARCA2 at the EPO promoter 
under hypoxia demonstrated the importance of this complex in HIF1A mediated 
activation of EPO gene[78]. SMARCA4 deletion also led to defects in erythropoiesis and 
vascular development in mouse models, which overlap with the known function of 
HIF1A targets such as VEGF. Mechanistically, HIF1 and HIF2 recruit SMARCA4 
containing SWI/SNF complex to HIF target genes promoter to facilitate ATP dependent 
chromatin remodeling and activation of HIF target genes [79]. These studies reflect the 
importance of SWI/SNF remodelers in hypoxia response, but the role of the accessory 
subunits and their mechanistic link to HIF1A need further investigation. Since research is 
now focusing on the importance of chromatin remodelers in hypoxia-mediated 
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metastasis, the SWI/SNF complex has received high levels of scrutiny and the functions 
of its subunits are being individually studied to identify new avenues to target metastatic 
disease progression.  
 
In this study, we analyzed two subunits of the SWI/SNF complex, SMARCE1 and 
SMARCA4, for their roles in breast cancer metastasis. Genome-wide transcriptome 
studies revealed that BRG1 controls the expression of PI3K/ AKT and BCL2 which are 
frequently altered in tumor cells [80]. In breast cancers, SMARCA4 is involved in 
progression and metastasis, therefore may serve as a novel biomarker, predictive of 
distant metastasis and patient outcomes [81]. SMARCE1, however does not possess any 
helicase or ATPase activity but has still been associated with invasive progression of 
breast cancer [82]. SMARCE1/BAF57 is an accessory subunit of the SWI/SNF complex 
whose function is not completely unraveled. 
 
 Orthotopic xenograft models were used to deduce the role of these transcriptional 
modulators in MDA-MB-231 cells, a triple negative breast cancer cell-line. A lung 
metastatic derivative of MDA-MB-231 (LM) established as previously described [83] 
was used to engineer derivatives stably expressing short hairpin RNA (shRNA) against 
KDM6B, EHMT2, SMARCA4, SMARCE1, BHLHE40 or empty vector (EV) through 
lentiviral transduction and selected in medium containing respective selection drug as 
shown in Table 1-1. Mice inoculated with tumor cells were inspected weekly for tumor 
appearance by visual observation and palpation. Primary tumor outgrowth was quantified 
twice a week using digital calipers. Tumor volume was calculated as: Volume = (width2 x 
length)/2. Tumor and lung tissues were extracted 6 weeks after inoculation. The left lung 
lobes were imaged using fluorescent microscopy, and metastatic foci in lungs were 
quantified using ImageJ software (Figure 1-7).   
 
 
BHLHE40 and SMARCE1 Knockdown Reduces Lung Metastasis of Breast Cancer 
In-Vivo 
 
Primary tumor growth rate was significantly reduced in the BHLHE40 
knockdown cells as shown in Figure 1-8A. Spontaneous lung metastatic foci were 
measured in percentage metastatic foci occupied in the lung parenchyma following six 
weeks of cell inoculation in the mammary fat pad of NSG mice. The mean metastatic foci 
of the LM cells and derivatives are as shown in Table 1-2. BHLHE40-KD (knockdown) 
and SMARCE1-KD both showed a substantial decrease in lung metastatic foci in lungs 
of mice, as shown in Figure 1-8B and C. In addition, BHLHE40 was shown to be 
essential for primary tumor growth. This study further investigates the underlying 
mechanisms which lead to reduction in the metastatic potential of breast cancer cells by 
BHLHE40-KD and SMARCE1-KD. 
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Table 1-1. shRNA construct information. 
 
Gene name Catalog# Company Selection drug  
SMARCA4 pBABE BRG1 Addgene 
Cambridge, MS, USA 
2µg/ml Puromycin 
Sigma-Aldrich 
 
BHLHE40 TRCN0000232187 
Sigma-Aldrich 
St.Louis, MO, USA 
2µg/ml Puromycin 
Sigma-Aldrich 
 
KDM6B MSCV JMJD3 
Addgene 
Cambridge, MA, USA 
2µg/ml Puromycin 
Sigma-Aldrich 
 
SMARCE1 TRCN0000015779 
Sigma-Aldrich 
St.Louis, MO, USA 
2µg/ml Puromycin 
Sigma-Aldrich 
 
EHMT2 
pLenti6-MK1-
EHMT2-V5 
Addgene 
Cambridge, MA, USA 
30µg/ml Blasticidine 
Sigma-Aldrich 
 
Control-
mCherry 
pEZX-AM03 
GeneCopoeia 
Rockville, MD, USA 
2µg/ml Puromycin 
Sigma-Aldrich 
 
 
Plasmids used for knockdown of gene of interest and the selection drug used for 
generation of stable knockdown cell line. 
 
 
 
 
E  
 
Figure 1-7. Orthotropic Xenograft model studies. 
 
5X105 fluorescently labelled cells were injected in the mammary fat pad of 4 weeks old 
NSG female mice and 40 days post injections the lungs were harvested and analyzed 
under the fluorescence microscope to detect the presence of metastatic foci. 
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Figure 1-8. Fluorescent Lung metastases. 
 
A. Primary tumor growth rate and B. percentage fluorescent lung metastatic foci in mice 
injected with LM cells transfected with empty vector (LM EV) and the knockdown 
derivatives, calculated using ImageJ software. p<0.05, n=10 C. Fluorescence pictures of 
lung metastasis pattern (10X). 
 
 
 
 
Table 1-2. Mean percentage of metastatic foci in-vivo.  
 
Cell line Mean % lung metastatic foci P value 
LM 12.35 ± 5.1  
LM EHMT2-KD 9.08 ± 2.6 0.094 
LM KDM6B-KD 8.51 ± 2.3 0.061 
LM SMARCA4-KD 9.38 ± 2.5 0.115 
LM SMARCE1-KD 1.02 ± 0.7  <0.00001 
LM BHLHE40-KD 7.42 ± 1.9 0.012 
 
Area of mean metastatic foci in mice lung parenchyma inoculated with LM cell lines and 
knockdown derivatives. (Highlighted cells show significant reduction in lung metastatic 
foci, p<0.05, n=10) 
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CHAPTER 2.    ROLE OF SMARCE1 IN METASTATIC BREAST CANCER* 
 
 
Introduction 
 
Breast cancer is the most frequently diagnosed form of cancer in American 
women and is the second leading cause of cancer related deaths, primarily due to the 
incurable nature of metastatic breast cancer [84]. Metastasis is the process whereby 
cancer cells spread from the site of the primary tumor to distant organs[10]. A stepwise 
sequence of events is involved in the metastatic process, during which the tumor cells 
encounter many environmental challenges such as loss of attachment to the extracellular 
matrix, physical stress during circulation in blood/lymph vessels and immune 
surveillance [85, 86]. Only a small fraction of disseminated cells can alter gene 
expression patterns to obtain new phenotypic features according to environmental cues, 
and ultimately survive and adapt to form metastatic lesions. The mechanics of this 
adaptability is an evolving field of study. 
 
Chromatin remodeling plays a key role in tumor progression by altering gene 
expression patterns to facilitate rapid adaptation of tumor cells to extracellular stimuli 
[87]. Aberrant chromatin remodeling activity is frequently detected in human tumors. 
High-throughput genome and/or exome sequencing studies have revealed that the 
SWI/SNF (switching-defective and sucrose non-fermenting) chromatin-remodeling 
complexes are the most highly mutated chromatin regulatory complexes, with nearly 20% 
of human cancers harboring mutations in at least one of the genes encoding SWI/SNF 
subunits [88]. Human SWI/SNF complexes consist of either BRG1/SMARCA4 or 
BRM/SMARCA2 subunit that possesses helicase and ATPase activity, and several 
BRG/BRM associated factors (BAFs) that regulate the DNA binding specificity and 
affinity of the complexes [88, 89]. The cancer-associated mutations cause aberrant 
activation of the residual SWI/SNF complexes due to distinct subunit configurations, 
rather than eliminating the chromatin remodeling activity [90-92]. Although earlier 
studies have identified several SWI/SNF subunits (e.g., SMARCB1 and SMARCA4) as 
tumor repressors, emerging evidence suggests that SWI/SNF activity is essential for 
tumor initiation, maintenance and progression [92, 93]. Therefore, it becomes critically 
important to define the role of each SWI/SNF subunit in development and progression of 
various types of tumors and adaptability of tumor cells to environmental cues.   
 
Genomic amplification of BAF57/SMARCE1, a core subunit of human SWI/SNF 
complexes that play a role in interaction with transcription factors and chromatin, has 
been linked to a high-risk of recurrence of estrogen/progesterone receptor-negative breast 
tumors [94]. However, the underlying molecular mechanisms remain undefined. In this 
study, we demonstrated that SMARCE1 plays a key role in breast cancer metastasis by 
protecting breast cancer cells during circulation against anoikis through the HIF1A/PTK2 
pathway.  
 
*Adapted with permission. Fan M, Sethuraman A, et al. “Role of SMARCE1 in 
metastatic breast cancer” Breast Cancer Res 2016 Aug 5;18(1):81. [95]   
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Methods 
 
 
Cell culture  
 
All cell lines were purchased from ATCC (Manassas, VA).  MDA-MB-231, 
HCC38, BT549 and their derivatives were maintained in Minimum Essential Media 
(Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS), 200 
units/ml penicillin-streptomycin (Cellgro, Manassas, VA, USA) and 0.5 µg/ml 
Amphotericin B (Cellgro, Manassas, VA, USA). 184B5 cells were cultured in Mammary 
Epithelial Cell Growth Medium (MEGM, Lonza, Switzerland). A lung metastatic 
derivative of MDA-MB-231 (LM) was established as previously described [83]. Cells 
stably expressing short hairpin RNA (shRNA) against SMARCE1, HIF1A, PTK2 or 
empty vector (EV) control were established by lentivirus transduction and selected in 
medium containing 2 µg/ml puromycin (Sigma, St Louis, MO, USA). pLKO.1-
HIF1AshRNA (NM_001530.x-1048s1c1), pLKO.1-SMARCE1shRNA 
(TRCN0000015779) and pLKO.1-PTK2shRNA (TRCN0000344599) were obtained from 
Open Biosystems/GE Dharmacon (Lafayette, CO, USA) and Sigma-Aldrich (St. Louis, 
MO, USA). Cells stably expressing FAK/PTK2 or SMARCE1 were obtained by 
lentiviral transduction and selected in medium containing 30 µg/ml blasticidine (Sigma). 
pLX304-PTK2 (HsCD00442503) and pLX304-SMARCE1 (HsCD00440078) were 
purchased from DNASU Plasmid Repository (Tempe, AZ).  Control cells were 
established by lentivirus transduction to express selection marker only. Accell 
SMARTpool (a mixture of 4 siRNA provided as a single reagent) for human SMARCE1 
was obtained from Dharmacon (GE Healthcare Life Sciences, PA) and used to 
knockdown SMARCE1 expression by following the manufacture’s protocol. The Accell 
Human Control siRNA (non-targeting) was used as control oligonucleotides. 
 
 
Orthotopic xenograft model and experimental lung metastasis model (tail-vein 
injection)  
 
All animal studies adhered to protocols approved by the Institutional Animal Care 
and Use Committee of University of Tennessee Health Science Center. For orthotopic 
xenograft model in NSG mice (NOD.Cg Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson 
Laboratory), cells (7.5x105 cells in 10 µl Phosphate-buffered saline) were surgically 
inoculated into the right inguinal mammary gland fat pads of 4-week old female mice as 
previously described [96]. Mice were inspected weekly for tumor appearance by visual 
observation and palpation. Primary tumor outgrowth was monitored twice a week using 
digital calipers. Tumor volume was calculated as: Volume = (width2 x length)/2. Tumor 
and lung tissues were extracted 6 weeks after inoculation. The left lung lobes were 
imaged under the fluorescent microscope, fixed with 4% paraformaldehyde, followed by 
tissue section (10µm) and hematoxylin and eosin staining. Metastatic foci in lungs were 
quantified using ImageJ software. For experimental lung metastasis model, cells were 
inoculated into to 4-week old NSG mice by tail vein injection. Whole blood was 
collected by cardiac puncture at various time and subjected to ficoll-paque separation as 
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per manufacturer’s protocol immediately after collection (Ficoll-Paque PLUS, GE 
Healthcare Life Sciences, Piscataway, NJ) to isolate circulating tumor cells. Fluorescent 
circulating tumor cells were counted under fluorescent microscope using a 10X objective.  
 
 
Quantitation of mRNA using qPCR  
 
Total RNA was prepared with Trizol (Life technologies, Grand Island, NY), 
chloroform and isopropanol. mRNA concentration and quality was analyzed on the 
NanoDrop (ThermoScientific, USA). cDNAs for mRNA were synthesized by using 
iScript cDNA Synthesis Kits (BioRad, Hercules, CA). qPCR was performed on the 
CFX96™ Real-Time PCR Detection System using SYBR Green Supermix (BioRad). 
Expression data of mRNA were normalized by the 2-ΔΔCT method to RPL13A, and 
presented as mean ± SE (n=3). qPCR primers were obtained from PrimerBank [97].  
 
 
Migration and invasion assays 
 
Cells (20,000 cells/0.5 ml/well) were plated onto control membrane inserts with 
8-micron pores (migration assay) or Matrigel-coated membrane transwell inserts 
(invasive assay) (BD Biosciences, Bedford, MA), which were placed in 24-well 
chambers filled with 0.6 ml growth medium. Twenty-four hours after plating, cells that 
remained on the upper surface of the membrane were removed by cotton tipped swabs, 
and cells that migrated/invaded to the lower surface of the membrane were viewed under 
the fluorescent microscope. The fluorescent cell pictures were analyzed on ImageJ and 
percent migration was expressed as % migration = (mean number of cells migrating 
through Matrigel insert membrane x 100/ mean seeding control) and percent invasion was 
expressed as: % invasion = (mean number of cells invading through Matrigel insert 
membrane x 100) / mean number of cells migrating through control insert membrane.  
 
 
Suspension culture and inhibitor assays  
 
To mimic loss of attachment, 105 cells/well were seeded in 6-well culture dishes 
coated with polyHEMA (Sigma, St Louis, MO, USA) to prevent cell adherence for 
various periods of time. Cells were inoculated with 3ml of growth medium initially with 
no further manipulation throughout the course of the experiment. Cell suspensions were 
placed into standard culture dishes 16 hours prior to end-point viable cell counting. 
 
To identify the signaling pathways that promote survival of detached cells, a 
panel of chemical inhibitors were added in culture medium to cells plated in polyHEMA 
coated dishes: PTK2/FAK inhibitor - 0.5 µM PF562271 (Selleckchem, Houston, TX), 
MAPK1/2 inhibitor – 10 µM U0126 (LC Laboratories, Woburn, MA) or 10 µM 
PD98059 (Santa Cruz Biotechnology, Dallas, TX), AKT inhibitor – 30 µM ZSTK474 
(LC Laboratories), TGFBRI/II inhibitor – 10 µM LY2109761 (Selleckchem), SRC 
inhibitor – 3 µM Dasnitib (LC Laoratories) or  Notch inhibitor – 5 µM DAPT 
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(Selleckchem). Following a 7-day incubation, cells were plated back on the standard 
culture dishes and quantified 16 hours later.   
 
 
Protein extraction and immunoblotting  
 
Protein extraction from whole cells was prepared with radioimmunoprecipitation 
buffer, cytosolic and nuclear fractions was prepared by NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (ThermoScientific). Protein lysates were resolved on 8-
10% SDS-PAGE and transferred to polyvinylidene fluoride membrane and 
immunoblotted with the following antibodies: anti-PTK2/FAK, FAK-Tyr576P/Tyr577P, 
MAPK1/2-Thr202P/Tyr204P, MAPK1/2, AKT-Tyr416P, AKT and BCL2L11 from Cell 
Signaling Technologies (Boston, MA); anti-HIF1A from Novus Biologicals (Littleton, 
CO); anti-SMARCE1 and SMARCA4 from Bethyl Laboratories (Montgomery, TX); 
anti-GAPDH from Millipore (Merck, Darmstadt, Germany) and anti-TBP from Abcam 
(Cambridge, MA). Luminescence detection of these membranes were performed as 
previously discussed [83].  
 
 
Chromatin immunoprecipitation  
 
Cells (2x107) were cross-linked with 1% formaldehyde (Pierce™ 16% 
Formaldehyde (w/v), Methanol-free, Life Technologies) for 15 minutes.  The nuclear 
fraction was prepared using the NE-PER™ Nuclear and Cytoplasmic Extraction 
Reagents (Life Technologies), chromatin was sheared by sonication to obtain ~500 bp 
fragments and the soluble fraction was collected after centrifuge (12,000rpm, 15 min). 
The soluble nuclear fractions were pre-cleaned with control IgG and MagnaBind Goat 
anti-Rabbit IgG (Life Technologies) and used for immunoprecipitation with antibodies 
against HIF1A, SMARCE1 or SMARCA4. Immunocomplexes were isolated with 
MagnaBind Goat anti-Rabbit IgG, de-crosslinked, and subjected to DNA preparation 
using the MiniElute PCR Purification Kit (QIAGEN, Germantown, MD). qPCR was 
performed to detect the presence of PTK2 promoter region by using primers (Forward: 
5’-CTCTTCCTCCTCCTGCCTCT-3’; reverse 5’-GTTCGGGGAAGACAGAAA GG-
3’). To detect protein-protein interaction, the immunocomplexes were dissolved in 
Laemmli Sample Buffer (Bio-Rad) and subjected to immunoblotting assay.   
 
 
Caspase assay 
 
5x105 cells were plated in polyHEMA coated dishes and Caspase-3 levels were 
measured at indicated time points using the Caspase-Glo® 3/7 assay kit (Promega). The 
cells were lysed with lysis buffer provided with the kit and substrate and lysis mix was 
incubated for 30 minutes with rotation and quantifies via luminometer. Caspase activity 
was calculated as per manufacturer protocol and, normalized to cell numbers.  
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Nucleosome scanning assay (NUSA)  
 
106 cells were placed under suspension culture in polyHEMA coated dishes for 0, 
0.5, 1 and 2 hours, respectively. Nuclei were isolated, treated with Atlantis Double-strand 
specific DNased (dsDNase) and subjected to DNA purification according to the EZ 
Nucleosomal DNA prep kit (Zymo Research). qPCR was performed to determine 
nucleosome positioning on the PTK2 promoter. Overlapping primers were designed from 
-150 to +1589 relative to start site of PTK2 promoter to generate amplicons of ~150 bp, 
the size of DNA covered by one nucleosome. DNA amount was calculated according to a 
standard curve (qPCR CTs vs. various concentrations of template) generated for each 
primer and normalized to qPCR CTs of DNA purified from equal number of nuclei 
untreated with dsDNAase.  
 
 
Statistical analysis  
 
ANOVA and post-hoc least significant difference analysis or t-tests were 
performed using GraphPad Prism 5 software. P values < 0.05 (*) were considered 
statistically significant. Data from two or three independent experiments with replicates 
are presented as means ± sd.  
 
 
Results 
 
 
SMARCE1 knockdown reduces lung metastasis of breast cancer in vivo 
 
To define the role of SMARCE1 in breast cancer metastasis, we examined the 
effect of SMARCE1 knockdown on spontaneous lung metastasis using an orthotopic 
xenograft mouse model derived from a lung metastatic variant of MDA-MB-231 cells, 
previously described and designated as LM [83]. SMARCE1 knockdown showed no 
significant effect on the latency and growth rate of primary xenografts in mammary gland 
fat pads (Figure 2-1A and B, LM-SMARCE1-KD vs. LM-EV), but substantially reduced 
both the number and size of metastatic foci in lungs (Figure 2-1C, LM-SMARCE1-KD 
vs. LM-EV). According to the images of lung tissue sections, metastatic foci occupied 
12.30 ± 3.87 % of the lung parenchyma in mice 6-wk after inoculation with LM-EV cells, 
which was reduced to 1.02 ± 0.76 % in mice inoculated with LM-SMARCE1-KD cells 
(p=0.0002) (Figure 2-1C, bar graph). By examining the number of tumor cells in blood, 
we found that SMARCE1 knockdown significantly reduced the number of circulating 
tumor cells (p=0.0011) (Figure 2-1D) in mice inoculated with LM cells. Together, these 
results suggest that SMARCE1 activity is dispensable for primary tumor outgrowth, but 
essential for distant metastasis of MDA-MB-231 cells.   
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Figure 2-1. SMARCE1 knockdown reduces lung metastasis of breast cancer in 
vivo.  
 
A. Expression levels of SMARCE1 mRNA and protein in LM-EV and LM-SMARCE1-
KD cells B. Effect of SMARCE1 knockdown on the growth of xenografts in the fourth 
inguinal mammary fat pads of female NSG mice, n=6 C. Spontaneous lung metastasis 
from orthotopic sites. Metastatic foci of tumor cells expressing red fluorescent protein on 
the dorsal surface of the left lung lobe were imaged 38 days after tumor cell inoculation 
(left panel). The presence of tumor cells in the lungs was visualized by hematoxylin and 
eosin (H&E) staining of formalin-fixed lung sections (10 μM) and quantified by ImageJ 
software (right panel) n=6. D. Number of circulating tumor cells in blood. Fluorescent 
tumor cells in mouse blood were isolated and counted 38 days after tumor cell 
inoculation. (n=5) 
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SMARCE1 knockdown reduces lung colonization of tumor cells inoculated through 
tail vein  
 
Metastasis is a multi-step process, involving local invasion, circulation, 
extravasation, colonization and outgrowth of metastatic foci [98]. To identify the steps of 
this metastatic cascade that requires SMARCE1 activity, we examined the effect of 
SMARCE1 knockdown on the ability of tumor cells to survive circulation and colonize 
lungs by using an experimental metastasis model. LM-EV and LM-SMARCE1-KD cells 
(5x105) were injected into the left lateral tail-vein of 5-wk old female NSG mice. Tumor 
cells in the bloodstream and lung tissues were examined at various time after injection 
(Figure 2-2A). As expected, the number of circulating tumor cells in blood decreased 
over time. Interestingly, at any given time point, the number of LM-EV cells in 
bloodstream was significantly higher than that of the LM-SMARCE1-KD cells (Figure 
2-2A). At 72 hours post tail vein injection, we analyzed whole lung lobes under 
fluorescent microscope and observed red fluorescent tumor cells in lungs of mice 
inoculated with LM-EV cells but not in mice with LM-SMARCE1-KD cells (Figure  
2-2B). Four weeks post injection, a lower number of tumor foci were observed in lungs 
of mice inoculated with LM-SMARCE1-KD cells compared to mice with LM-EV cells 
(Figure 2-2C). Together, these results suggest that SMARCE1 knockdown diminishes 
the ability of tumor cells to survive circulation, thus leading to an overall reduction of 
lung metastatic foci in mice injected with SMARCE1 knockdown cells. 
 
 
SMARCE1 knockdown sensitizes tumor cells to anoikis 
 
Our in vivo experiment results implicate SMARCE1 as an essential contributor in 
distant metastasis of breast cancer cells by promoting the survival of circulating tumor 
cells. However, it is unclear whether SMARCE1 plays a role in early metastatic events 
such as cell migration and invasion. To examine the effect of SMARCE1 knockdown on 
the migratory and invasive potential of tumor cells, we performed Boyden Chamber 
Transwell assays. Cells were plated in uncoated Boyden chambers to measure their 
migratory potential, and in matrigel coated chamber to determine their invasiveness. As 
showed in Figure 2-3A, SMARCE1 knockdown in LM cells significantly increased cell 
migratory potential, but showed no significant effect on cell invasiveness. This 
observation suggests that SMARCE1 activity is dispensable for cell migration. Next, we 
examined the effect of SMARCE1 knockdown on cell sensitivity to anoikis by 
monitoring cell viability after cultured in dishes coated with PolyHEMA to prevent 
attachment.  As showed in Figure 2-3B, SMARCE1 knockdown in LM cells 
substantially reduced the number of viable cells cultured in suspension. This result is 
consistent with our results from in vivo experiments and confirms that SMARCE1 plays a 
key role in protecting LM cells against anoikis, a form of cell death induced by 
detachment.  
 
To determine whether SMARCE1-mediated anoikis resistance ability can be 
extended to other breast cancer cell lines, we examine the effect of SMARCE1  
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Figure 2-2. SMARCE1 knockdown reduces lung colonization of tumor cells 
inoculated through tail veins.  
 
A. Number of circulating tumor cells in blood collected at various time points after tail 
vein injection in NSG mice. B. Fluorescent tumor cells in lungs of NSG mice 72h after 
tail vein injection. Representative images of five lungs for each group were shown. C. 
Fluorescent tumor foci in the left lung lobes of NSG mice 4-wk after tail vein injection of 
tumor cells. The area of tumor foci on the dorsal surface of the left lung lobe was 
quantified by ImageJ. 
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Figure 2-3. SMARCE1 knockdown promotes cell migration, but sensitize cells to 
anoikis. 
 
A. Effect of SMARCE1 knockdown in LM cells on cell migration and invasion. Boyden 
chambers, uncoated or coated with matrigel were used to measure cell migratory and 
invasive potential, respectively. Percent migration/invasion was calculated as per 
manufacturer’s protocol B. Effect of SMARCE1 knockdown in LM cells on viability of 
cells cultured in dishes coated with PolyHEMA to prevent adhesion. C. Effect of 
SMARCE1 knockdown in HCC38 cells. D. SMARCE1 overexpression in BT549 cells. 
E. Blocking SMARCE1 expression by siRNA enhanced detachment-induced caspase 
activation in LM and HCC38 cells. Accell SMARTpool of SMARCE1-siRNA (1 µM) 
were delivered into cells 48 h prior to detachment. Caspase activities were determined at 
indicated time point after cell detachment by using the Caspase-Glo 3/7 assay kit. 
*p<0.05, n=6, Student T-test. 
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knockdown in HCC38 (Figure 2-3C), a triple-negative breast cancer cell line. We found 
that SMARCE1 knockdown resulted in significant reduction of the viability of cells in 
suspension culture. In addition, we examined the effect of SMARCE1 overexpression in 
BT549, a triple-negative breast cancer cell line that lacks SMARCE1 expression due to a 
biallelic inactivating mutation that causes a frameshift [99]. As expected, no SMARCE1 
mRNA or protein was detected in BT549 cells (Figure 2-3D). Enforced SMARCE1 
overexpression in BT549 substantially increased the viability of cells in suspension 
culture. To validate the observations with SMARCE1-shRNA, we examined the effect of 
SMARCE1 siRNA (Accell SMARTpool, GE Dharmacon) or control oligonucleotides on 
anoikis in LM and HCC38 cell lines. As showed in Figure 2-3E, SMARCE1 siRNA 
(SMARCE1-i) treatment resulted in decreased expression of SMARCE1 protein and 
enhanced activation of caspase 3/7 in cells under suspension culture. These results 
demonstrate that SMARCE1 plays role in anoikis resistance of breast cancer cells.  
 
 
SMARCE1-mediated anoikis resistance requires activation of PTK2, MAPK and 
AKT pathways  
 
To gain insights into the molecular mechanisms underlying SMARCE1-mediated 
anoikis resistance, we sought to identify signaling pathways regulated by SMARCE1 in 
detached cells by using chemical inhibitors of several signaling pathways that have been 
linked to anoikis resistance of cancer cells [100, 101]. As showed in Figure 2-4A, 
inhibitors of focal adhesion kinase (PTK2/FAK), MAPK and AKT significantly reduced 
the viability of LM-EV cells in suspension culture. In contrast, these inhibitors showed 
no significant effect on LM-SMARCE1-KD cells. The same experiments were performed 
with BT549-EV and BT549-SMARCE1 cells and the result showed that SMARCE1-
mediated increase of cell viability was effectively abolished by inhibitors of PTK2, 
MAPK and AKT (Figure 2-4B). In agreement with the observed effects of chemical 
inhibitors on cell viability, immunoblotting analysis showed that LM-EV cells in 
suspension culture had higher levels of PTK2 protein, MAPK phosphorylation and AKT 
phosphorylation compared to LM-SMARCE1-KD cells (Figure 2-5A). In addition, 
elevated expression of the pro-apoptotic protein BIM/BCL2L11, a marker of onset of 
anoikis in breast cancer cells, was detected in suspension cultures of LM-SMARCE1-KD 
cells, but not in LM-EV cells (Figure 2-5A). Consistently, higher levels of PTK2 protein 
and AKT phosphorylation, concomitant with lower levels of BIM protein, were observed 
in HCC38-EV cells as compared to HCC38-SMARCE1-KD cells in suspension culture 
(Figure 2-5B). However, MAPK phosphorylation was not affected by cell detachment or 
SMARCE1 knockdown in the HCC38-EV cells. In addition, elevated expression levels of 
PTK2 protein, MAPK phosphorylation and AKT phosphorylation, but diminished levels 
of BIM, were detected in BT549-SMARCE1 cells in comparison to control BT549-EV 
cells under suspension culture (Figure 2-5C). Together, these results suggest that 
activation of PTK2, MAPK and AKT survival pathways are critical for breast cancer 
cells to survive anoikis, and SMARCE1 activity is required for the activation of these 
pro-survival pathways in detached cells.  
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Figure 2-4. SMARCE1-mediated anoikis resistance requires activation of PTK2, 
MAPK and AKT pathways.  
 
A. Viability of LM-EV and LM-SMARCE1-KD cells cultured in PolyHEMA-coated 
dishes in the absence or presence of indicated inhibitors. B. Viability of BT549-EV and 
BT549-SMARCE1 cells cultured in PolyHEMA-coated dishes in the absence or presence 
of indicated inhibitors. For all experiments, viable cells were counted after 7 days in 
suspension culture. Concentration of inhibitors: 0.5µM PF562271, 10µM U0126, 10µM 
PD98059, 30µM ZSTK474, 3µM Dasnitib, 5µM DAPT and 10µM LY2109761. *p<0.05, 
n=3, Student T-test. 
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Figure 2-5. SMARCE1-dependent activation of PTK2, MAPK and AKT 
pathways by cell detachment.  
 
A. Effect of SMARCE1 knockdown in LM cells on detachment-induced activation of 
pro-survival (FAK/PTK2, MAPK and AKT) and pro-apoptotic (BIM) signaling 
pathways. B.  Effect of SMARCE1 knockdown in HCC38 cells. C. Effect of SMARCE1 
overexpression in BT549 cells. The levels of protein expression and phosphorylation 
were determined by immunoblotting assays. GAPDH was included as a loading control. 
 
 
  
 29 
SMARCE1 collaborates with HIF1A to activate PTK2 transcription in detached 
cells 
  
Aberrant activation of PTK2, a non-receptor tyrosine kinase involved in focal 
adhesion, has been recognized as a key mediator of anoikis resistance in variety of tumor 
cells [100, 102]. For example, PTK2 activation has been detected in circulating tumor 
cells isolated from 90% of patients with metastatic breast tumors, implicating a role of 
PTK2 in breast cancer metastasis [103]. Therefore, we sought to examine whether 
SMARCE1 regulates PTK2 expression in detached cells. Based on immunoblotting and 
qPCR analysis, we found that cell detachment induced PTK2 expression at both the 
protein level (Figure 2-5) and mRNA level (Figure 2-6A) in a SMARCE1-dependent 
manner in LM, HCC38 and BT549 cells. This observation suggests that SMARCE1 is 
required for PTK2 gene activation on a transcriptional level in detached cells.  
 
By inspecting the transcription factor binding consensus sequences in the 
proximal promoter region of PTK2 gene (Figure 2-6B), we found a potential 
HIF1A/ARTN binding site located in the binding region of SWI/SNF subunits 
(SMARCA4 and SMARCB1) identified by ENCODE TFBS ChIP-seq analysis [104]. 
Normoxic HIF1A activation has been linked to anoikis resistance in breast cancer cells 
[103, 105]. In addition, SWI/SNF complexes were reported to play a role in modulating 
HIF1A-mediated transcription activation in cells under hypoxia [79, 106]. Therefore, we 
speculated that SMARCE1 regulates PTK2 gene transcription through HIF1A in detached 
cells. Using CHIP-qPCR assays, we showed that that cell detachment induced 
recruitment of SMARCE1, HIF1A and BRG1/SMARCA4 to the PTK2 promoter region 
(-874 to -575 bp) in LM-EV cells, which was abolished by SMARCE1 knockdown 
(Figure 2-6B). In addition, using reciprocal immunoprecipitation assays, we detected 
HIF1A and SMARCE1 proteins in the immunoprecipitated SMARCE1 and HIF1A 
complexes, respectively (Figure 2-6C). These results suggest that SMARCE1 activity is 
required for HIF1A-mediated PTK2 transcription activation in detached cells.  
 
Since the SWI/SNF complex is involved in nucleosomal remodeling we sought to 
examine changes in the nucleosomal positioning on the PTK2 promoter. Nucleosome 
scanning assay (NUSA) was performed to examine the consequence of SMARCE1 and 
HIF1A binding to the PTK2 promoter in detached cells. We found that cell detachment 
induced nucleosomal disassembly on the PTK2 promoter region bound by HIF1A and 
SMARCE1, indicated by increased sensitivity of PTK2 promoter to dsDNase digestion, 
which resulted in decreased amount of DNA detected by qPCR (Figure 2-7). However, 
cell detachment did not increase dsDNase sensitivity of PTK2 promoter in LM-
SMARCE1-KD cells (Figure 2-7B, right panel). These observations support the role of 
SMARCE1 in chromatin remodeling of PTK2 promoter and HIF1A-mediated PTK2 
transcriptional activation in detached cells. 
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Figure 2-6. SMARCE1 collaborates with HIF1A to activate PTK2 transcription 
in detached cells.  
 
A. Detachment-induced PTK2 mRNA expression is abolished by SMARCE1 knockdown 
in LM and HCC38 cells, whereas enhanced by SMARCE1 overexpression in BT549 
cells. B. Detachment-induced recruitment of HIF1A and SMARCA4 to the promoter 
region of PTK2 is diminished by SMARCE1 knockdown in LM cells. Chromatin binding 
of HIF1A, SMARCE1 and SMARCA4 was measured by ChIP-qPCR assay. Average 
fold enrichment of PTK2 promoter DNA by indicated antibodies (vs. control IgG) from 
three independent experiments are presented. C. Detachment induces interaction between 
SMARCE1 and HIF1A in LM-EV and LM-SMARCE1-KD cells. The protein interaction 
was examined by Immunoprecipitation/Immunoblotting assays. *p<0.05, Student T-test. 
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Figure 2-7. SMARCE1 orchestrates chromatin remodeling of PTK2 promoter in 
detached cells.  
 
A. Overlapping primer designed for the nucleosome scanning assay and their amplicon 
sizes. The location of each primer set is given relative to the transcription start site (TSS). 
B. Significant nucleosomal displacement is observed on PTK2 promoter (from -802 to -
492 bp, encompassing HIF1A binding site) in LM-EV cells after 0.5, 1 and 2 hours under 
suspension culture (vs. adherent cells), but not in LM-SMARCE1-KD cells. Results from 
three independent experiments were presented as means ± SE.  
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HIF1A activates PTK2 transcription and downstream activation of survival 
pathways in detached cells 
  
To confirm that HIF1A-mediated PTK2 transcription is critical for breast cancer 
cell to survive anoikis, we examined the effect of HIF1A knockdown on cell sensitivity 
to anoikis and detachment-induced activation of PTK2, MAPK and AKT. HIF1A 
knockdown in MDA-MB-231 cells effectively dampened detachment-induced HIF1A 
protein accumulation and PTK2 mRNA expression (Figure 2-8A and B), and reduced the 
number of viable cells in suspension culture (Figure 2-8C). Immunoblot analysis showed 
levels of PTK2, phosphorylated-PTK2 (pTyr576/577), phosphorylated-MAPK 
(pThr202/Tyr204) and phosphorylated-AKT (pTyr416) were significantly lower in 
HIF1A-KD cells than that in control MDA-MB-231-EV cells under suspension culture 
(Figure 2-8D). Conversely, the pro-anoikis protein BIM was induced only in detached 
HIF1A-KD cells. To confirm that MAPK and AKT phosphorylation are downstream 
events of PTK2 activation in detached cells, we examined the effect of PTK2 inhibition 
by PF562271 on activation of these pathways. As showed in Figure 2-8E, pre-treatment 
with PF562271 effectively abolished detachment-induced phosphorylation of PTK2, 
MAPK and AKT.  Taken together, these results suggest that HIF1A-mediated PTK2 
transcription activation plays a key role in protecting cells against anoikis by sustaining 
the activation of survival signaling pathways (MAPK and AKT), as well as suppressing 
pro-apoptotic signaling (BIM).  
 
To corroborate the role of PTK2 in SMARCE1-mediated anoikis resistance, we 
examined the effects of PTK2 overexpression and PTK2 knockdown on anoikis 
sensitivities of LM-SMARCE1-KD and BT549-SMARCE1 cells, respectively. We found 
that PTK2 overexpression effectively rescued LM-SMARCE1-KD cells from anoikis, 
which is indicated by increased number of viable cells and reduced caspase activation 
(Figure 2-9A, B, C, and D). Conversely, PTK2 knockdown abolished SMARCE1-
mediated protection of BT549 cells against anoikis (Figure 2-9E and F).  
 
 
SMARCE1 knockdown sensitizes non-tumorigenic mammary epithelial cells to 
anoikis 
  
To examine whether the SMARCE1-dependent anoikis resistance occur at early 
stage of tumorigenesis, we examined the effect of SMARCE1 knockdown on anoikis 
sensitivity of 184B5, a mammary epithelial cell line immortalized by benzo(a)pyrene 
exposure [107]. Previous studies showed that 184B5 was not tumorigenic in 
immunosuppressed mice, but 184B5 does not form colonies in semisolid medium [107]. 
Therefore, 184B5 represents cells at early stage of tumorigenesis. We found that 
SMARCE1 inhibition in 184B5 cells, by either stable knockdown through shRNA 
expression (Figure 2-10A) or transient siRNA delivery (Figure 2-10B), blocked 
detachment-induced PTK2 upregulation (Figure 2-10C) and sensitized cells to anoikis, 
indicated by reduced cell numbers and increased caspase activation (Figure 2-10A and 
B, respectively). These observations suggest that SMARCE1/PTK2-mediated anoikis 
resistance is an early event of tumorigenesis.    
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Figure 2-8. HIFIA activates PTK2 transcription and downstream survival 
pathways in detached cells.  
 
A. Detachment induced HIF1A protein accumulation is eliminated by HIF1A knockdown 
in MDA-MB-231 cells. B. HIF1A knockdown abolishes detachment induced PTK2 
mRNA expression in MDA-MB-231 cells. C. HIF1A knockdown sensitizes MDA-MB-
231 cells to anoikis. Viable cells in suspension culture for 10 days were counted. D. 
Effect of HIF1A knockdown in MDA-MB-231 cells on detachment-induced activation of 
pro-survival (PTK2, MAPK and AKT) and pro-apoptotic (BIM) signaling pathways. E. 
Effect of PTK2 inhibition in MDA-MB-231 cells on detachment-induced activation of 
pro-survival and pro-apoptotic signaling pathways. The mRNA levels were measured by 
qPCR. The levels of protein expression and phosphorylation were determined by 
immunoblotting assays with GAPDH included as a loading control. *p<0.05, Student T-
test. 
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Figure 2-9. PTK2 activation is essential for SMARCE1-mediated anoikis 
resistance in breast cancer cells.  
 
A. Expression levels of PTK2 mRNA in LM derivatives. B. PTK2 protein expression and 
phosphorylation in LM derivatives cultured in PolyHEMA-coated dishes. Intensities of 
immunoblotting signals were quantified by ImageJ and the average of normalized 
intensities (vs. GAPDH) from three independent experiments were presented. C. Effect 
on PTK2 overexpression on viability of LM derivatives cultured in PolyHEMA-coated 
dishes. D. Effect on PTK2 overexpression on caspase activation in LM derivatives 
cultured in PolyHEMA-coated dishes. Caspase activity was normalized to cell numbers 
and results from three independent experiments were presented as means ± SE. E. 
Expression levels of PTK2 mRNA in BT549 derivative. F. Effect of PTK2 knockdown 
on viability of BT549 derivative cultured in PolyHEMA-coated dishes. *p<0.05, Student 
T-test, LM= lung metastatic derivative of MDA-MB-231 cells. 
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Figure 2-10. Blocking SMARCE1 expression sensitizes non-tumorigenic mammary 
epithelial cells to anoikis.  
 
A. Effect of SMARCE1 knockdown by stable shRNA expression on viability of 184B5 
cells cultured in PolyHEMA-coated dishes. B. Effect of stable shRNA expression 
(SMARCE1-KD) and SMARCE1-siRNA delivery (SMARCE1-i) on caspase activation 
in 184B5 cells cultured in PolyHEMA-coated dishes. Caspase activity was measured by 
using the Caspase-Glo 3/7 assay kit and normalized to cell numbers. The results from 
three independent experiments were presented as means ± SE. C. Detachment-induced 
PTK2 mRNA expression is abolished by SMARCE1-KD or SMARCE1-i in 184B5 cells. 
mRNA levels were measured by qPCR. *p<0.05, n=3, Student T-test. 
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Higher SMARCE1 and PTK2 expression is associated with poor prognosis of 
patients with basal-like or luminal B subtype of breast tumors 
 
Having established a role of SMARCE1 in regulating metastatic potential of 
breast cancer cells through the HIF1A/PTK2 pathway, we sought to elucidate the clinical 
relevance of this finding by examining the relationship between the SMARCE1 and 
PTK2 expression and the clinical outcomes of breast cancer patients. Analyzing 
expression data of 3554 breast tumor samples collected by an online Kaplan-Meier 
survival analysis tool [108], we found that higher expression of SMARCE1 or PTK2 is 
associated with shorter interval of relapse free survival (RFS) of breast cancer patients 
(Figure 2-11A). However, this RFS was not correlated when tumor samples were 
grouped according to ESR1 expression or intrinsic PAM50 subtype markers. Next, we 
examined the relationship between the expression of SMARCE1 and PTK2 in breast 
tumors in The Cancer Genome Atlas (TCGA) database [109]. No significant correlation 
between SMARCE1 and PTK2 expression was detected when data from all breast tumors 
(n=825) were included in the analysis. However, after tumors were stratified according to 
the intrinsic PAM50 subtype markers, a positive correlation between SMARCE1 and 
PTK2 expression was detected in the luminal B and basal-like cohorts (Figure 2-11B), 
but not in the human epidermal growth factor receptor 2, ERBB2-enriched or Luminal A 
cohorts. Together, these observations suggest that higher expression of SMARCE1 and 
PTK2 increases risk of tumor relapse, and SMARCE1 likely plays a key role in 
regulating PTK2 expression in luminal B and basal-like tumors.  
 
 
Genomic alterations contribute to deregulation of SWI/SNF complexes in breast 
cancer 
 
Despite the prevalent notion that SWI/SNF complexes are  tumor suppressors 
[110], emerging evidence suggests that genetic alterations of subunit genes can produce 
aberrant SWI/SNF complexes with oncogenic function [111]. These findings prompted 
us to examine the nature and frequency of genetic alterations in SMARCE1 and other 
SWI/SNF subunits specifically in breast cancer by using the TCGA database. The result 
revealed that approximately 30% breast tumors harbor genetic alterations in one or more 
of the genes encoding SWI/SNF subunits (Figure 2-11C). Interestingly, gene 
amplification is the most frequent genetic event for multiple SWI/SNF subunits in breast 
cancer, rather than inactive mutations that were reported in other tumors [88]. SMARCE1 
is the second most frequently amplified gene among all the SWI/SNF subunits. This 
finding implicates an oncogenic role of SWI/SNF complexes in human breast cancer. If a 
SWI/SNF subunit plays a critical role in promoting progression of breast cancer, we 
speculate a positive correlation between its expression and poor prognosis of breast 
cancer patients. Therefore, we examined the relationship between the expression of each 
SWI/SNF subunit and interval of RFS of breast cancer patients using the online Kaplan-
Meier survival analysis tool [108]. This analysis revealed higher expression of 9 (out of 
31) SWI/SNF subunits (i.e., BCL7C, BRD7, ACTL6A, SMARCE1, SMARCA5, 
SMARCAL1, SMARCA4, SS18 and SMARCC1) is associated with shorter interval of 
RFS of breast patients (LogRank p<0.05, n=3550). Overall the  
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Figure 2-11. Higher SMARCE1 and PTK2 expression is associated with poor 
prognosis of breast cancer patients.  
 
A. Kaplan-Meier analysis of recurrence-free survival (RFS) of breast cancer patients 
based on SMARCE1 and PTK2 expression using dataset of 3554 breast tumor samples 
(http://kmplot.com/analysis/). To construct Kaplan-Meier curves all percentiles between 
the lower and upper quartiles were computed and the best performing threshold was used 
as cutoff to divide the patient cohort. The LogRank test P value was calculated by using 
RFS up to 15 years as endpoint. B. Correlated expression of SMARCE1 and PTK2 in 
basal-like and luminal B subtypes of breast cancer according to the TCGA database. 
Tumors with PTK2 amplification were excluded from the correlation analysis. C. 
Frequency of genetic alterations of SWI/SNF complex subunits in breast tumors 
according to the TCGA database. 
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results from genetic and expression data analysis suggest that deregulation of SWI/SNF 
activity by altering expression of core subunits likely plays a key role in promoting breast 
cancer progression.   
 
 
Discussion 
  
Loss of adhesion to extracellular matrix (ECM) triggers a specific form of 
apoptosis termed anoikis in normal epithelial cells [112], which plays a fundamental role 
in morphogenesis of the mammary gland ductal system [113]. Circumvention of anoikis 
contributes to breast tumor development and is a prerequisite for metastases by allowing 
cells to survive loss or alterations of ECM [85, 100]. In mammary epithelial cells, the 
dynamic and magnitude of activation of pro-apoptotic genes (e.g., BIM and BMF) or pro-
survival proteins (e.g., PTK2) were shown to play a critical role in determining the fates 
of detached cells, anoikis or survival [38, 85, 100, 114]. PTK2 is one of the most 
important signaling proteins recruited into focal adhesions upon cell-ECM contact, where 
PTK2 is rapidly auto-phosphorylated to enable the recruitment of other scaffold and 
signaling molecules to activate the downstream cell survival signaling pathways (e.g., 
PI3K/Akt and MAPK/ERK pathways) [102, 114, 115]. Emerging evidence suggests that 
PTK2 plays a key role in protecting tumor cells against anoikis by sustaining survival 
signaling [100, 102]. However, how PTK2 is activated in detached cells has not been 
definitively resolved. Our studies revealed a key role of SMARCE1 in promoting 
survival of detached cells by facilitating rapid PTK2 transcription activation through 
HIF1A, the master regulator of hypoxia responsive genes. Multiple kinases were reported 
to activate PTK2 through phosphorylation at Tyr576/577 in detached cells, including 
SRC family kinases and PTK6 [100, 116]. We found that SRC inhibition by Dastinib, a 
SRC family tyrosine kinase inhibitor, had no effect on viability of LM and BT549 cells 
under suspension. This observation suggests that PTK2 phosphorylation in detached 
breast cancer cells is likely sustained by an SRC-independent mechanism.    
 
HIF1A activation under normal oxygen tension has been linked to anoikis 
resistance of breast cancer cells driven by the ERBB2 oncogene [105], and circulating 
breast tumor cells from patients with metastatic breast cancer [103]. SWI/SNF complexes 
were shown to regulate transcription activation of a subset of HIF1A target genes under 
hypoxia [106]. However, it is unclear whether the SWI/SNF complex is required for 
HIF1A transcription activity in detached cells under normal oxygen tension.  Our study 
provides evidence suggesting an essential role of SMARCE1-based chromatin 
remodeling activity in breast cancer metastasis by facilitating HIF1A mediated PTK2 
transcription activation in detached cells under normoxia. Further study is warranted to 
evaluate the anti-metastastic potential of approaches targeting SMARCE1-HIF1A 
interaction. 
 
According Project Achilles, the database which performed genome-wide pooled 
shRNA screens across hundreds of cancer cell lines to identify genes essential for tumor 
cell proliferation, SMARCE1 knockdown showed limited effect on proliferation of breast 
cancer cells [117]. Consistently, we found that SMARCE1 knockdown had no 
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significantly effect on proliferation of breast cancer cell lines -MDA-MB-231 and 
HCC38; in vitro and growth of orthotopic xenografts derived from MDA-MB-231 cells. 
However, SMARE1 knockdown did significantly enhanced anoikis sensitivity of breast 
cancer cells. These findings suggest that SMARCE1 is dispensable for proliferation of 
breast cancer cells under normal growth condition, but required for cells to survive 
anoikis. Whether SMARCE1 plays a role in protecting cells against stress-induced cell 
death in general requires further investigation. 
 
In contrast to colorectal cancer, melanoma or lung cancers which frequently 
harbor inactive mutations of SWI/SNF subunits, breast tumors have a relatively low 
frequency of inactive mutations [88, 92, 93]. By inspecting the TCGA database we found 
that ~30% breast tumors harbor genetic alterations (e.g., gene amplification, deletion and 
mutation) in one or more of the SWI/SNF subunits, with gene amplification being the 
most frequent event. This finding implicates an oncogenic role of SWI/SNF complexes in 
breast cancer. Consistently, we found that higher expression of several SWI/SNF 
subunits was associated with shorter interval of RFS of breast cancer patients. Our 
findings are likely relevant to basal-like and luminal B breast tumors subtypes, due to a 
positively correlated expression profile between SMARCE1 and PTK2. In conclusion, 
this study establishes a novel role of SMARCE1 in regulating metastatic potential of 
breast cancer cells by promoting survival of detached cells through the HIF1A/PTK2 
pathway.  
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CHAPTER 3.    ROLE OF BHLHE40 IN BREAST CANCER METASTASIS 
 
 
Introduction 
 
One in every eight women in the United States will be diagnosed with breast 
cancer over the course of her lifetime [118]. An estimated 266,120 new cases are 
expected, and 40,920 women are expected to die from breast cancer in 2018 in the United 
States [118]. Distant metastasis is the major cause of breast cancer related deaths. 
Hypoxia has been recognized as a primary driving force of distant metastasis of breast 
cancer [19, 49, 119-122]. Among hypoxia responsive genes are both promoting and 
suppressive factors for malignant progression. It is unclear how the expression and 
activities of metastasis-promoting factors are preferentially augmented in metastatic 
tumors. A large body of studies have focused on elucidating the molecular mechanisms 
by which hypoxia enables cancer cells to survive a variety of stresses imposed during the 
metastatic cascade, including nutrient depletion, loss of attachment and deprivation of 
growth factors. 
 
Hypoxia-induced exosomic secretion of cytokines and growth factors plays a key 
role in promoting metastasis through both tumor autonomous and non-autonomous 
mechanisms [123, 124]. Exosomes are microvesicles (40–130 nm) constitutively released 
by a variety of cells into the extracellular environment to promote cell-to-cell 
communication [125]. Tumor cells have been reported to utilize exosomes to transfer 
nucleotides, lipids and proteins into surrounding cells or cells in distant metastatic niches 
[125, 126]. Hypoxia is known to markedly increase the number of secreted exosomes, as 
well as alter the contents of exosomes [127]. However, our understanding of the 
regulation of exosome secretion is rudimentary. 
 
Although the cellular response to hypoxia is mainly controlled by two basic helix-
loop-helix transcription factors, HIF1A and EPAS1/HIF2A, the outcomes of hypoxia 
response are modified by other transcription regulators that are regulated by hypoxia or 
interact with HIF1A or EPAS1 [128, 129]. This study focuses on the role of a basic helix 
loop helix transcription factor BHLHE40 (also known as DEC1/ BHLHB2/ SHARP2/ 
STRA13) in metastasis of breast cancer. BHLHE40 expression is directly activated by 
HIF1A in a variety of tumor cells under hypoxia [130, 131]. High BHLHE40 expression 
has been linked to activation of hypoxia response pathway, elevated metastatic potentials 
and poor prognosis of various types of tumors, including hepatocellular carcinoma, 
pancreatic cancer and invasive breast cancer [132-134]. It is reported that BHLHE40 
binds to the E-box elements and regulates the expression of genes associated with 
circadian rhythm, cell differentiation, cell senescence, lipid metabolism, DNA damage 
response and immune response [135-138].  
 
However, the action mechanism and downstream targets of BHLHE40 in breast 
cancer cells are largely unknown. In this study, we provide evidence that BHLHE40 is a 
pro-metastasis factor in breast cancer cells that promotes tumor cell survival and 
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migration by modulating exosomic secretion of HBEGF, a heparin binding epidermal 
growth factor.  
 
 
Methods  
 
 
Cell culture 
 
Breast cancer MDA-MB-231 and MCF7 cells were obtained from ATCC 
(Manassas, VA, USA) and maintained in Minimal Essential Medium (ThermoFisher 
Scientific, Rockford, IL, USA) supplemented with 10% fetal bovine serum (FBS), 200 
U/ml of penicillin-streptomycin and 0.5 g/ml amphotericin B (Cellgro, Manassa, VA, 
USA). A lung metastatic derivative of MDA-MB-231 (LM) and a tamoxifen-resistant 
derivative of MCF7 (TR) were established as described previously [139, 140]. A stable 
line (BHLHE40-KD) expressing a short hairpin RNA against BHLHE40 
(TRCN0000232187, Sigma-Aldrich, St Louis, MO, US) were generated by lentiviral 
transduction and selected in medium containing 2 g/ml puromycin (Sigma-Aldrich). A 
colony of BHLHE40 knockout variant (BHLHE40-KO) of MDA-MB-231 was generated 
by using the CRISPR/Cas9 all-in-one expression system (HCP221270-CG01-1, 
GeneCopoeia) and selected in medium supplemented with 500 g/ml of gentamicin. To 
knockout HIF1A and EPAS1 by CRISPR/Cas9 editing, gRNA targeting exon 1 of HIF1A 
or EPAS1 was individually cloned into the pX462-puromycin and pX462-hygromycin 
vectors (expressing Cas9n, AddGene), respectively. MDA-MB-231 cells were transfected 
with pX462-puro-HIF1A gRNAs using FuGene HD followed by selection in puromycin. 
A clonal line that had no HIF1A protein detected by immunoblotting was transfected 
with pX462-hygromycin-EPAS1 gRNA and selected by hygromycin. Hygromycin-
resistant colonies that had no EPAS1 detected by immunoblotting were pooled to 
generate a HIF1A/EPAS1 double knockout (HIF-dKO) subline. For all KD or KO 
sublines, control cells were transfected with corresponding empty vectors (EV) and 
selected in antibiotics in parallel with cells transfected with shRNAs or gRNAs. Pooled 
drug-resistant colonies of control cells were used as EV control lines.  
 
 
Orthotropic xenograft and experimental lung metastasis models 
 
All in vivo studies were performed in accordance with the protocols approved by 
the Institutional Animal Care and Use Committee (IACUC) of the University of 
Tennessee Health Science Center. NOD. Cg PrkdcscidIl2rgtm1Wjl/Szj (NSG) mice were 
purchased from Jackson Laboratories (Bar Harbor, ME, USA). Orthotropic xenograft and 
experimental lung metastasis (tail-vein injection) models were established by using 
fluorescence labelled tumor cells, as previously described [95, 139]. Tumor size was 
monitored and measured weekly using digital calipers. Tumor volume was calculated as: 
volume = (width2 x length)/2. Lung metastasis was quantified by fluorescent imaging of 
lungs and qPCR of human Alu DNA repeats (Forward primer: 5’: 
GTCAGGAGATCGAGACCATCCC 3’, Reverse primer: 5’: 
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TCCTGCCTCAGCCTCCCAAG 3’). Circulating tumor cells in whole blood (collected 
by cardiac puncture) were isolated by using the Ficoll-Paque PLUS medium (GE 
Healthcare Life Sciences, Piscataway, NJ, USA) and counted under fluorescent 
microscope. 
 
 
Migration, invasion and wound healing assays 
 
Transwell membrane inserts with 8-micron pores (BD Biosciences, Bedford, MA, 
USA), uncoated or coated with Matrigel, were used to determine the migratory and 
invasive activities of cancer cells, respectively. Cells undergoing migration and invasion 
were expressed as: Percent migration = mean number of cells migrating through the 
uncoated transwell x 100 / mean number of seeded cells. Percent invasion = mean 
number of cells migrating through the matrigel-coated transwell x 100 / mean number of 
migrating cells through the uncoated pores). Real-time assessment of migratory activity 
during scratch-wound healing was performed by using the IncuCyte ZOOM-ImageLock 
plate system (Essen Bioscience, Michigan, USA). To examine the expression levels of 
proteins in response to scratch wounds, the EMD Millipore Chemicon Cell Comb Scratch 
assay kit (Millipore) was used to generate a high-density field of scratches in a confluent 
cell monolayer to maximize the area of wound edges. To examine the effect of HBEGF 
on cell migration and invasion, a neutralizing antibody of HBEGF (10 g/ml, AF-259-
NA, R&D systems, Minneapolis, MN, USA) or a HBEGF peptide (20 g/ml) was added 
to the medium.  
 
 
Suspension culture, viable cell counting and caspase assays 
 
To mimic the loss of attachment, cells were cultured in PolyHEMA (Sigma 
Aldrich) coated plates to prevent adherence. Methylcellulose (1%) was added into 
medium to prevent formation of large cell aggregates to accurately measure tumor cell 
proliferation in suspension. Viable cells were counted by Trypan Blue exclusion method. 
Cell apoptosis was determined by using the caspase Glo 3/7 assay kit (Promega, 
Madison, Wi, USA) or immunoblotting of cleaved Caspase 9. 
 
 
Luciferase reporter assay for HIF activity 
 
Luciferase reporter constructs driven by hypoxia responsive elements of LDHA 
(LDHA-Luc, S721613) and ITGA6 (ITGA6-Luc, S708174) were purchased from 
SwitchGear Genomics (Carlsbad, CA, USA). Cells (3x105) were transfected with 500ng 
LDHA- or ITGA6-Luc and 10 ng CMV--Galactosidase (control for transfection 
efficiency), along with 250ng of an empty vector or a HIF1A-expressing construct 
(HsCD00444875, DNASU plasmid repository), by using Fugene6 (Promega). Forty-eight 
hours after transfection the cells were exposed to hypoxia (1% O2) for six hours. 
Luciferase and -gal activities were measured by using the LightSwitch Luciferase Assay 
 43 
System and Promega Beta-Glo Assay System, respectively. Relative luciferase activities 
normalized to -gal were presented as: mean ± SD, n=6. 
 
  
Exosome isolation and analysis 
 
To isolate exosomes, 5x106 cells were cultured in medium supplemented with 
exosome-free serum (SystemBio, Palo Alto, CA, USA). Exosomes in the conditioned 
medium were purified by using the ExoQuick-TC solution (SystemBio), and quantified 
under a fluorescent microscope after labeled with carboxyfluorescein diacetate 
succinimidyl ester (CFSE) by using the Exo-Glow labeling kit (SystemBio) that is 
designed to exclude background particles. To analyze the protein content, isolated 
exosomes were lysed in RIPA buffer (Pierce, ThermoScientific) containing protease 
inhibitor cocktail (SigmaAldrich) and subjected to immunoblot analysis. To examine the 
effect of purified exosomes on cell migration, exosomes were re-suspended in exosome-
free medium and added to cells seeded in Transwells to evaluate migration. 
 
 
Gene expression microarray and qPCR analysis 
 
Total RNA from cells exposed to hypoxia (1% O2 for 6 and 48h) was purified by 
using the RNeasy kits (Qiagen) and submitted to the Molecular Resource Center at 
University of Tennessee Health Science Center for labelling and hybridization to the HT-
12 expression BeadChips (Illumina, Chicago, IL, USA). Hybridization signals were 
processed for annotation, background subtraction, quantile normalization and presence 
call filtering by using the Gene Expression Module of the GenomeStudio Software 
(Illumina). The microarray data can be found in the Gene Expression Omnibus database 
with accession number of GSE107300 (secure token: wbafiwcgptkvjwf). Hypoxia 
responsive genes were defined as genes whose expression was altered by ≥1.5 fold 
(hypoxia vs. control) in two independent experiments. BHLHE40 target genes were 
defined as genes whose expression was altered by ≥1.5 fold (BHLHE40-KD vs. EV) in 
two independent experiments. To examine the effect of BHLHE40-KD on gene 
expression in cells exposed to hypoxia (1% O2) in combination with low glucose (1 mM) 
(1%O2/LG), a condition frequently encountered by cells in solid tumors, total RNAs of 
cells exposed to (1%O2/LG for 4h from three independent experiments were pooled and 
analyzed using the GeneChip Human Gene 1.0 ST array (Affymetrix, Santa Clara, CA, 
USA). The Affymetrix data were extracted, normalized, and summarized with the robust 
multi-average (RMA) method implemented in the Affymetrix Expression Console. To 
validate microarray data by qPCR, total RNAs from cells in three independent 
experiments with duplicates was prepared by using trizol (Life Technologies, Grand 
Island, NY, USA). cDNA’s were synthesized using iScript cDNA Synthesis kits (Bio-
Rad, Hercules, CA, USA) and qPCR was performed on the CFX96TM Real-Time PCR 
detection system by using SYBR green supermix (Bio-Rad). Expression data of mRNA 
were normalized by the 2-ΔΔCT method to RPL13A and presented as mean ± standard 
deviation (SD). Primers of qPCR were obtained from the Primerbank [141]. 
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Protein extraction, co-immunoprecipitation and immunoblotting 
 
For immunoblotting (IB) analysis, whole cell lysates and nuclear proteins were 
prepared by using RIPA buffer supplemented with protease inhibitor cocktails (Sigma-
Aldrich) and the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo 
Scientific), respectively. To detect protein-protein interaction, soluble proteins were 
extracted by using the Pierce IP Lysis Buffer (Thermo Scientific) supplemented with 
protease inhibitor cocktails and co-immunoprecipitation was performed by using the 
TrueBlot Immunoprecipitation and Western Blot Kit (Rockland Immunochemicals Inc., 
Limerick, PA). IB signals were developed by using the SuperSignal West Dura Extended 
Duration Substrate and the CL-XPosure Film (Thermo Scientific). Antibodies used in this 
study were: anti-EGFR-Tyr1110P, anti-EGFR, anti-ERK1/2-Thr202/Tyr204P, anti-
ERK1/2, anti-AKT-Tyr416P, anti-AKT, anti-Caspase9, anti-HDAC1 and anti-HDAC2 
from Cell Signaling Technologies (Boston, MA, USA); anti-GAPDH from Millipore 
(Merck, Darmstadt, Germany); anti-TBP from Abcam (Cambridge, MA, USA); anti-
CTGF from Abgent (San Diego, CA, USA); anti-HBEGF and anti-CD9 from R&D 
Biosystems (Minneapolis, MN, USA); anti-BHLHE40, anti-HIF1A and anti-EPAS1 from 
Novus Biologicals (Littleton, CO, USA); and anti-ALIX, anti-TSG101, anti-CD81 from 
Santa Cruz (Dallas, TX, USA). 
 
 
Chromatin immunoprecipitation  
 
Protein-DNA crosslink, nuclear fraction extraction and chromatin fragmentation 
were performed as described previously [95]. Soluble fraction of sheared chromatin (200-
500bp in length) was pre-cleaned with Magnabind Goat anti-Rabbit IgG (for anti-
BHLHE40 and anti-HDAC1) or Magnabind Goat anti-Mouse (for anti-HDAC2) (Life 
Technologies), followed by immunoprecipitation with control IgG or antibodies against 
BHLHE40, HDAC1 or HDAC2, and Magnabind beads conjugated with a secondary 
antibody. DNA in the decrosslinked immunocomplexes was isolated with the MiniElute 
PCR purification kit (Qiagen, Germantown, MD, USA). qPCR was performed to detect 
the presence of proximal promoter region of HBEGF (-529 to -372 from the transcription 
start site) by using the following primers: forward 5’ TGCCTGCAACTTCAACT CTG 
3’ and reverse 5’ CCATCCCTGTCACCCTCTAA 3’. 
 
 
Statistical analysis  
 
Student’s t-tests, one-way ANOVA with post-hoc Tukey test and Pearson r 
correlation significance analyses were performed by using the GraphPad Prism 5 
software (Graphpad, San Deigo, CA, USA); p values <0.05 (*) were considered 
statistically significant. 
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Results 
 
 
BHLHE40 knockdown leads to decreased primary tumor growth and lung 
metastases 
 
To define the role of BHLHE40 in breast cancer metastasis, we examined the 
effect of its knockdown (KD) by a shRNA lentiviral construct on spontaneous lung 
metastasis of orthotopic xenograft tumors derived from a lung metastasis-enriched 
subline (LM) of breast cancer MDA-MB-231 cells [83]. The protein levels of BHLHE40 
is significantly induced by hypoxia (1% O2, 16h). BHLHE40-shRNA expression 
effectively reduced both baseline and hypoxia-induced levels of BHLHE40 in LM cells 
(Figure 3-1A). In NSG mice inoculated with 2x105 control LM-EV (empty vector) cells 
in the inguinal mammary gland fat pads, palpable tumors were detected at 2 weeks 
(Figure 3-1B) and lung metastasis became evident at 5 weeks (Figure 3-1C) post-
inoculation. BHLHE40-KD delayed the onset of primary tumors, which became palpable 
3 weeks after inoculation, and reduced the growth rate of primary tumors, coincident with 
decreased lung metastases (Figure 3-1A, B, and C). To further investigate the effect of 
BHLHE40-KD on lung metastases, primary tumors of EV and BHLHE40-KD cells were 
surgically removed at 3 and 5 weeks post-inoculation, respectively, when they reached 
similar size with a diameter of 4-5 mm. Lung metastasis was examined four weeks after 
primary tumor resection (Figure 3-1D). BHLHE40-KD substantially reduced lung 
metastasis in mice with similar primary tumor burdens. Taken together, these results 
suggest that BHLHE40 plays a role in promoting primary tumor growth and spontaneous 
distant metastasis of breast cancer cells.  
 
 
BHLHE40 knockdown reduces lung colonization of tumor cells inoculated through 
tail vein 
 
To determine whether BHLHE40 regulates late metastatic events after entry of 
tumor cells into blood stream, we examined the effect of BHLHE40-KD on the ability of 
tumor cells to survive circulation and colonize in the lungs by using an experimental 
metastasis model, in which tumor cells were delivered into blood stream through tail-vein 
injection to bypass the initial steps of metastasis, namely, migration and intravasation. 
LM-EV and LM-BHLHE40-KD cells (5 × 105) were injected into the left lateral tail-vein 
of 5-week-old female NSG mice, and tumor cells in the bloodstream and lung tissues 
were examined at various time-points post-injection (Figure 3-2). Compared to control 
LM-EV cells, LM-BHLHE40-KD cells were more rapidly eliminated from the 
bloodstream (Figure 3-2A). LM-EV cells were observed in lung tissues at 72 hours and 
formed large metastatic foci at 4 weeks after tail vein injection (Figure 3-2B and C). In 
contrast, BHLHE40-KD cells were not detected in lung tissue at 72h, and formed lower 
metastatic foci in lungs than EV cells at various time points (Figure 3-2B and C). No 
fluorescent loci of EV or BHLHE40-KD cells were found in other organs (i.e., livers, 
spleens and kidneys) within 5 weeks after tail vein inoculation. Together, these results 
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Figure 3-1. BHLHE40 knockdown (KD) significantly reduced primary tumor size 
and lung metastatic burden in an orthotopic xenograft model.  
 
A. BHLHE40-shRNA expression effectively reduced both baseline and hypoxia-induced 
expression of BHLHE40 protein in the LM cells, as determined by Immunoblotting. B. 
Orthotopic xenograft tumors derived from LM-BHLHE40-KD cells exhibited lower 
growth rate than tumors derived from control LM EV (empty vector) cells. NSG mice 
were inoculated in the inguinal mammary gland fat pads with 2x105 cells. Tumor size was 
monitored and measured weekly by using a digital caliper. Tumor volume was calculated 
as: volume = (width2 x length)/2. *p<0.05 (n=20, KD vs. EV at indicated time points), 
One-way ANOVA followed by Tukey's post-hoc tests. C. Spontaneous lung metastasis 
detected by fluorescent imaging of lungs or human ALU repeats qPCR 5-wk after 
inoculation of tumor cells in mammary gland fat pads. *p<0.05 (n=10, KD vs. EV), 
student’s t test. D. Lung metastasis in mice after resection of primary tumors. Primary 
tumors in mammary gland fat pads were resected when they reached a size of 5 x 5 mm 
and lung metastasis were analyzed 4 weeks post-resection by fluorescent imaging of 
lungs or human ALU repeats qPCR. *p <0.05, (n=10, KD vs. EV), student’s t test. 
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Figure 3-2. BHLHE40 knockdown (KD) reduced lung colonization of tumor cells 
inoculated into the circulation via tail veins.  
 
A. Less tumor cells were detected in blood of NSG mice inoculated via tail vein injection 
with LM BHLHE40-KD than mice inoculated with empty vector control LM EV cells. 
Tumor cells in whole blood collected by cardiac puncture at indicated times after tail vein 
injection were isolated by using the Ficoll-Paque PLUS medium and counted under 
fluorescent microscope. *p<0.05 (n=3, KD vs. EV), One-way ANOVA followed by 
Tukey's post-hoc tests. B. Fluorescent imaging of metastatic foci in lungs at different 
time points post tail-vein injection. C. Percentage of areas occupied by metastatic loci in 
the lungs, as quantified by fluorescent imaging and ImageJ. *p<0.05, (n=3, KD vs. EV), 
One-way ANOVA followed by Tukey's post-hoc tests. 
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suggest that BHLHE40 is required for tumor cells to survive circulation and establish 
metastatic foci in the lungs. 
 
 
BHLHE40 acts to promote cell migration, invasion and survival 
 
Having established a role of BHLHE40 in distant metastasis of breast cancer cells 
in vivo, we sought to identify the specific cellular processes that require BHLHE40 
activity. Despite the significant effect of BHLHE40-KD on primary tumor growth and 
lung metastasis of LM cells in vivo, BHLHE40-KD showed no significant effect on 
proliferation of LM cells under normal 2-D growth conditions in vitro. The doubling 
times, determined by trypan blue exclusion-based cell counting (daily for 7 days), of LM-
EV and LM-BHLHE40-KD cells were 36.37 ± 0.49 h (n=6) and 38.95 ± 3.61 h (n=6), 
respectively. Therefore, we focused on investigating whether BHLHE40 is a downstream 
effector of HIF1A activation by hypoxia or loss of attachment. Detached breast cells were 
reported to rely on HIF1A activation to survive under normoxia [142]. In vitro cell 
migration and invasion assays showed that BHLHE40-KD reduced the ability of cells to 
penetrate either uncoated or matrigel-coated transwells under hypoxia condition (1% O2, 
Figure 3-3A). Under the non-adherent culture condition for 15 days, in which cells were 
mixed with growth medium supplemented with 1% methylcellulose to prevent cell 
aggregation and then seeded in plates coated with polyHEMA to prevent adherence, the 
number of viable LM BHLHE40-KD cell was significantly lower than LM EV cells 
(Figure 3-3A, lower panel). To examine whether the effects exerted by BHLHE40-KD 
on LM cells can be extended to the parent MDA-MB-231 cells, we established a 
BHLHE40 knockout (KO) subline by using the CRISPR/Cas9 editing system. BHLHE40 
protein depletion in the KO subline under normoxia or hypoxia was confirmed by 
immunoblotting (Figure 3-3B, upper panel). BHLHE40-KO resulted in reduced number 
of viable cells after a 15-day suspension culture in plates coated with polyHEMA to 
prevent attachment (Figure 3-3B, middle panel), while showed no significant effect on 
number of viable cells after a 5-day adherence culture. In addition, BHLHE40-KO 
significantly sensitized MDA-MB-231 cells to apoptosis induced by hypoxia in 
combination with glucose depletion (1%O2/GF, 6h), as evidenced by the appearance of 
apoptotic morphology and activation of caspase3/7 (Figure 3-3B, lower panel).  
 
We further examined the function of BHLHE40 in breast tumor cells with 
elevated baseline activation of HIF1A and BHLHE40 by using the tamoxifen-resistant 
(TR) and fulvestrant-resistant (FR) variants of MCF7 cells [140]. As shown in Figure 3-
3C, mRNA expression levels of BHLHE40 and HIF1A are significantly elevated in TR 
and FR cells in comparison to parent MCF7 cells. BHLHE40-KD in TR cells 
substantially increased apoptosis induced by glucose depletion, under both normoxia and 
hypoxia conditions, as well as reduced number of viable cells after a 15-day suspension 
culture in polyHEMA-coated plates (Figure 3-3C). Collectively, these observations 
provide evidence supporting a role of BHLHE40 in promoting survival and migration.  
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Figure 3-3. BHLHE40 depletion impaired cell migration, invasion and survival.  
 
A. BHLHE40 knockdown (KD) by shRNA in LM cells reduced cell migration and 
invasion, as well as the number of viable cells during suspension culture in comparison to 
LM EV cells. Migratory and invasive activities were determined by using Transwells, 
uncoated or coated with Matrigel, respectively. Suspension culture was conducted by 
seeding cells in medium containing 1% Methylcellulose and in dishes coated with 
PolyHEMA for 15 days. *p <0.05 (n=6, KD vs. EV), student’s t test. B. BHLHE40 
knockout (KO) by CRISPR/Cas9 editing in MDA-MB-231 cells reduced the number of 
viable cells after suspension culture and enhanced apoptosis induced by hypoxia 
combined with glucose depletion (1%O2/GF). Viable cells were determined by trypan 
blue exclusion-based cell counting after a 15-day suspension culture. Apoptosis of cells 
exposed to 1%O2/GF for 6h was examined by the appearance of apoptotic morphology 
(as indicated by arrows in the cell images) and Caspase3/7 assays. *p <0.05 (n=6, KO vs. 
EV), One-way ANOVA followed by Tukey's post-hoc tests. C. BHLHE40-KD by 
shRNA in tamoxifen-resistant subline of MCF7 (TR) reduced the ability of cells to 
survive 1%O2/GF (6h) and reduced number of viable cells after a 15-day suspension 
culture. Elevated expression of HIF1A and BHLHE40 in TR and Fulvestrant-resistant 
(FR) sublines of MCF7 cells were detected by qPCR. BHLHE40-KD was confirmed by 
immunoblotting. Apoptosis induced by 1%O2/GF (6h) was determined by Caspase3/7 
assays. Number of viable cells after a 15-day suspension culture was determined by 
trypan blue exclusion-based cell counting.  **P<0.05 (n=6, TR or FR vs. parent MCF7), 
*p<0.05 (n=6, KD vs. EV), One-way ANOVA followed by Tukey's post-hoc tests.  
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BHLHE40 is required for transcription activation of a set of cytokines and growth 
factors 
 
To delineate the molecular pathways regulated by BHLHE40, we performed 
global gene expression analysis of LM-EV and LM BHLHE40-KD cells exposed to 
hypoxia (1% O2, 6h or 48h). The microarray data can be found in the Gene Expression 
Omnibus database with accession number of GSE107300. Overall, the expression levels 
of 521 and 646 genes in LM-EV cells were altered (fold change ≥1.5 in two independent 
experiments) by hypoxia at 6h and 48h, respectively. BHLHE40-KD abolished the 
hypoxia-mediated upregulation of 45 (out of 261, 17.2%) and 98 (out of 361, 27.1%) 
genes at 6h and 48h, respectively. In addition, BHLHE40-KD abolished the hypoxia-
mediated downregulation of 30 (out of 260, 10.5%) and 44 (out of 285, 15.4%) genes at 
6h and 48h, respectively. The hypoxia-induced genes that were affected by BHLHE40-
KD were overrepresented by genes that encode proteins with cytokine or growth factor 
activities as defined by Gene Ontology annotation (GO:0005125 and GO:0008083, 
Fisher’s exact p <0.0001) (Figure 3-4A). The expression of a subset of these genes was 
also reduced in BHLHE40-KD cells exposed to 1%O2/LG for 4h, compared to EV cell 
(Figure 3-4B). In contrast, hypoxia-induced expression of a panel of the core hypoxia 
responsive genes that are known to be directly targeted by HIF1A [129] was not 
significantly affected by BHLHE40-KD (Figure 3-4C). These observations suggest that 
BHLHE40-KD preferentially reduced hypoxia-induced expression of a set of cytokines 
and growth factors, but did not cause a global defect in HIF1A-mediated transcription 
activation. To confirm this notion, we examined the effect of BHLHE40-KO on HIF-
mediated expression of reporter luciferase driven by well-characterized HIF1A-binding 
sites in the promoter regions of LDHA and ITGA6 [26-28]. As showed in Figure 3-4D, 
BHLHE40-KD exhibited no significant effect on hypoxia-induced luciferase activities, in 
the absence or presence of exogenous HIF1A protein. The effect of BHLHE40-KD on 
expression of cytokines and growth factors in cells exposed to 1%O2/LG (4h) was 
validated by qPCR (Figure 3-4E). Consistent with results in BHLHE40-KD cells 
cultured in vitro, we detected reduced expression of connective tissue growth factor 
(CTGF) and HBEGF, at both mRNA and protein levels, in the LM-BHLHE40-KD 
primary tumors in comparison to LM-EV tumors established in mouse mammary gland 
fat pads (Figure 3-4F).  
 
To determine whether BHLHE40-mediated expression of genes encoding 
cytokine or growth factors is relevant to clinical samples, we analyzed the mRNA 
expression data of breast tumors in the TCGA database [109, 143]. The expression of 
71.4 % (20 out of 28) of these BHLHE40-dependent genes (as showed in Figure 3-4A) 
was found to be positively correlated with BHLHE40 expression with statistical 
significance (p <0.05) in at least one of the four major subtypes of breast tumors (Table 
3-1). This observation provides supporting evidence for a role of BHLHE40 in the 
expression of these genes in human breast tumors. 
 
Since hypoxia-induced cytokines and growth factors are commonly exported to 
extracellular space by exosomes [144], we sought to determine whether BHLHE40-KD 
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Figure 3-4. BHLHE40 knockdown reduced hypoxia-induced expression of a panel 
of cytokines and growth factors.  
 
A. Heatmaps of cytokines and growth factors whose hypoxia-induced expression (1% O2 
at 6h or 48h, fold change ≥ 1.5 in two independent experiments) was diminished by 
BHLHE40-knockdown (KD) in LM cells. The gene expression levels were determined 
by using the Illumina Human HT-12 expression BeadChips. Normalized (Quantile 
normalization) hybridization signals were log2 transformed and standardized by genes 
across experiment conditions to generate heatmap. B. Heatmaps of a subset of genes list 
in A whose expression was affected by BHLHE40-KD in LM cells exposed to hypoxia 
combined with low (1mM) glucose (1%O2/LG, 4h). The gene expression levels were 
determined by using the Affymetrix Human Gene 1.0 ST array. C. Heatmaps of hypoxia-
induced genes whose expression was not significantly affected by BHLHE40-KD in LM 
cells as determined the Illumina Human HT-12 expression BeadChips. D. Expression of 
luciferase reporters driven by hypoxia-responsive elements of ITGA6 or LDHA was not 
affected by BHLHE40 knockout (KO) by CRISPR/Cas9 editing in MDA-MB-231 cells, 
in the absence or presence of exogenous HIF1A. Luciferase activities were normalized to 
co-transfected CMV--galactosidase and presented as mean±SD (n=6). E. Expression of 
genes in control LM EV and LM BHLHE40-KD cells exposed to 1%O2/LG (4h). mRNA 
expression levels were determined by qPCR, normalized to RPL13A, and presented as 
mean±SD (n=6). *p<0.05 (n=6, 1%O2/LG vs. untreated control), **p<0.05 (n=6, KD vs. 
EV), One-way ANOVA followed by Tukey's post-hoc tests. F. mRNA and protein 
expression levels of HBEGF and CTGF in primary xenograft tumors, determined by 
qPCR and immunoblotting, respectively. *p<0.05 (n=6, KD vs. EV), Student’s t test. 
Representative Immunoblotting images of 3 tumors of KD or EV cells were presented.  
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Table 3-1. Correlated expression of BHLHE40 and its putative targets in breast 
tumors (TCGA). 
 
  
Gene 
BL (n=230)  Her2 (n=162)  LA (n=315)  LB (n=300) 
Pearson 
r value 
P value  Pearson 
r value 
P value  Pearson 
r value 
P value  Pearson 
r value 
P value 
CCL3L1 0.1210 0.0694  -0.2045 0.0095  0.0504 0.3792  0.0480 0.4136 
CMTM3 -0.0042 0.9494  0.0358 0.6510  0.5065 < 0.0001  -0.0521 0.3687 
CMTM7 -0.2761 < 0.0001  -0.0697 0.3780  0.2516 < 0.0001  0.0635 0.2729 
CMTM8 -0.1580 0.0165  -0.0886 0.2624  0.1034 0.0670  -0.0013 0.9817 
CSPG5 -0.1333 0.0435  -0.0309 0.6961  -0.0351 0.5345  -0.0504 0.3850 
CTGF 0.0203 0.7593  0.3087 < 0.0001  0.4876 < 0.0001  0.0631 0.2760 
EBI3 0.2135 0.0011  -0.2060 0.0085  0.0805 0.1543  -0.0271 0.6402 
EDN1 0.0705 0.2867  0.0928 0.2401  0.3805 < 0.0001  0.0273 0.6379 
FGF1 0.1666 0.0114  0.2470 0.0015  0.4225 < 0.0001  0.0357 0.5384 
FGF13 -0.1105 0.0946  -0.1782 0.0233  0.1393 0.0134  -0.1276 0.0271 
FLT3LG 0.2436 0.0002  -0.0588 0.4573  0.2878 < 0.0001  -0.0264 0.6487 
GMFG 0.2593 < 0.0001  -0.1764 0.0247  0.3367 < 0.0001  -0.1271 0.0277 
HBEGF 0.3871 < 0.0001  0.2873 0.0002  0.3254 < 0.0001  0.1577 0.0062 
IL11 0.1413 0.0322  0.1762 0.0249  0.2053 0.0002  0.0328 0.5710 
IL12A 0.0325 0.6207  -0.0582 0.4618  -0.1035 0.0649  -0.1543 0.0069 
IL15 0.3407 < 0.0001  0.0628 0.4273  0.1632 0.0037  -0.0913 0.1146 
IL17A 0.1036 0.1139  0.0845 0.2850  -0.0221 0.6942  -0.0919 0.1094 
IL1A 0.2140 0.0013  -0.0057 0.9440  0.0399 0.4960  -0.0720 0.2359 
IL25 -0.1011 0.3633  0.0560 0.6578  -0.1569 0.0293  0.1617 0.0661 
IL32 0.1597 0.0153  -0.0571 0.4704  0.3242 < 0.0001  -0.0473 0.4141 
JAG2 -0.0418 0.5287  0.0387 0.6250  0.0880 0.1190  -0.0167 0.7729 
MDK -0.0837 0.2057  -0.0947 0.2305  0.1107 0.0496  0.0066 0.9099 
NAMPT 0.2678 < 0.0001  0.0873 0.2691  0.1667 0.0030  -0.1819 0.0016 
NRTN -0.4457 < 0.0001  -0.0350 0.6596  0.0672 0.2411  -0.0288 0.6220 
TFF1 0.2156 0.0009  -0.0148 0.8516  0.0221 0.6936  -0.1243 0.0300 
TNFSF12 0.1690 0.0102  -0.0271 0.7323  0.1482 0.0084  0.0565 0.3296 
VEGFB -0.0460 0.4879  0.0811 0.3049  0.2028 0.0003  0.0443 0.4449 
VEGFC 0.3664 < 0.0001  0.1760 0.0251  1.0000 < 0.0001  -0.0922 0.1110 
 
HBEGF expression is significantly correlated with BHLHE40 in basal-like, Her2-
positive, Luminal A, and Luminal B subtypes of breast cancer. The correlation analysis 
was performed using the mRNA expression Z-scores (RNA Seq V2 RSEM, TCGA). BL, 
basal-like; Her2, ERBB2-enriched; LA, Luminal A; LB, Luminal B. (Highlighted cells 
show significant positive correlation) 
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could affect exosome secretion. As shown in Figure 3-5, the numbers of isolated 
exosomes were significantly reduced in the conditioned medium from MDA-MB-231 
BHLHE40-KO and TR-BHLHE40-KD cells in comparison to the corresponding control 
cells cultured under both normal condition or exposed to 1%O2/LG for 6h. The presence 
of exosomic markers (i.e., CD9, CD81, ALIX and TSG101) [145, 146]) in the isolated 
exosomes was confirmed by immunoblotting (Figure 3-5). BHLHE40 depletion reduced 
protein levels of HBEGF in the purified exosomes (Figure 3-5), reflecting the reduced 
levels of HBEGF mRNA and HBEGF protein in whole cell extracts of BHLHE40-KD or 
KO cells (Figure 3-4E and Figure 3-5). These observations suggest that BHLHE40-
depletion reduced exosome secretion because of reduced expression of cytokines and 
growth factors. 
 
 
BHLHE40 activates HBEGF transcription by sequestering HDAC1 and HDAC2 
from promoter binding 
 
Among the cytokines and growth factors affected by BHLHE40-KD in LM cells, 
the expression level of HBEGF mRNA is positively correlated with the expression level 
BHLHE40 mRNA in all four major subtypes of breast tumors in the TCGA database 
(Figure 3-4, Figure 3-5 and Table 3-1). HBEGF is a heparin-binding EGF-like growth 
factor that promotes cell proliferation and invasion through EGFR activation [147]. To 
examine the molecular mechanism underlying BHLHE40-mediated HBEGF 
transcription, we performed ChIP analysis. BHLHE40 binding to the proximal promoter 
region of HBEGF was not affected by 1%O2/LG (data not shown), indicating that 
HBEGF transcription activation was not caused by increased BHLHE40-DNA binding. 
However, 1%O2/LG treatment reduced binding of HDAC1 and HDAC2 to the HBEGF 
promoter (Figure 3-6A), which is coincident with increased BHLHE40-HDAC1/2 
interaction in the soluble cellular fraction, as detected by reciprocal Co-
immunoprecipitation (CoIP) followed by immunoblotting (IB) (Figure 3-6B). In cells 
lacking BHLHE40, HDAC1/HDAC2 remained bound to the promoter region of HBEGF 
after 1%O2/LG treatment (Figure 3-6A). This result suggests that BHLHE40 plays a role 
in facilitating dissociation of HDAC1/2 from promoters through protein-protein 
interaction. To examine whether HDAC1/2-DNA binding plays a key role to suppress 
transcription of BHLHE40 target genes, we examine the effect of HDAC inhibitors on 
mRNA expression of HBEGF, CTGF and VEGFC. As shown in Figure 3-6C, both 
HDAC2-specific (BRD6688, 10 M) and pan-HDAC inhibitor (TSA, 2M) increased 
expression of BHLHE40 target genes in MDA-MB-231 EV and BHLHE40-KD cells, 
supporting a role of HDAC1/2 in suppressing transcription of BHLHE40 target genes. 
Taken together, these observations suggest that sequestering HDAC1/2 from DNA 
binding contributes to BHLHE40-mediated transcription activation. 
 
 
HBEGF acts to promote cell survival and migration 
 
To examine whether BHLHE40-driven HBEGF expression plays a role in EGFR 
activation to promote cell survival, we examined the phosphorylation status of EGFR and  
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Figure 3-5. Exosomic secretion of HBEGF was reduced by BHLHE40 depletion in 
MDA-MB231 or TR cells.  
 
A. BHLHE40-KO by CRISPR/Cas9 editing in MDA-MB-231 cells reduced the total 
number of exosomes and the amount of HBEGF protein in exosomes in comparison to 
empty vector control EV cells. B. BHLHE40 knockdown (KD) by shRNA in TR cells 
reduced the total number of exosomes and the amount of HBEGF protein in exosomes in 
comparison to TR EV cells. Exosomes were purified from conditioned medium of 5x106 
cells cultured in medium supplemented with exosome-free serum, either under normal 
culture condition or exposed to 1%O2/LG for 6h. Exosomes were purified by using the 
ExoQuick-TC solution and quantified under a fluorescent microscope after labeled with 
carboxyfluorescein diacetate succinimidyl ester (CFSE) by using the Exo-Glow labeling 
kit, which is designed to exclude background particles. Exosome number in the bar graph 
is presented as mean number of exosomes per field ± SD (total 9 fields from three 
independent experiments were examined). The presence of HBEGF and exosome 
markers in purified exosomes (3 g protein/lane) or whole cell extracts (WCE, 30 g 
protein/lane) were detected by immunoblotting. **P<0.05 (n=9, 1%O2/LG vs. control), 
*p <0.05 (n=9, KO or KD vs. EV), One-way ANOVA followed by Tukey's post-hoc 
tests.  
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Figure 3-6. BHLHE40 activates gene expression by sequestering HDAC1 and 
HDAC2 from genome DNA binding in MDA-MB-231 cells exposed to hypoxia and 
low glucose (1%O2/LG, 4h). 
 
A. BHLHE40-knockout (KO) diminished dissociation of HDAC1 and HDAC2 from the 
promoter region of HBEGF in MDA-MB-231 cells exposed to 1%O2/LG (4h), as 
determined by chromatin immunoprecipitation (ChIP) followed by qPCR of the HBEGF 
promoter region (-529 to -372 from the transcription start site). HBEGF promoter binding 
activity of HDAC1 or HDAC2 was calculated as: [(DNA amount in anti-HADC IP 
complex - DNA amount in control IgG IP complex)/DNA amount in 1% input]. *p<0.05 
(n=6, 1%O2/LG vs. control), **p<0.05 (n=6, KO vs. EV). B. 1%O2/LG treatment 
increased interactions between BHLHE40 and HDAC1/2 in the soluble cellular fraction 
of MDA-MB-231 EV cells. Protein-protein interaction was detected by reciprocal co-
immunoprecipitation (IP)/immunoblotting (IB) analysis. C. HDAC inhibition induced 
expression of BHLHE40 target genes. Cells were exposed to hypoxia (1% O2) or HDAC 
inhibitors (BRD6688 10M or TSA 2M) for 24 h. mRNA expression levels were 
determined by qPCR, normalized to RPL13A, and presented as mean±SD (n=6). *p 
<0.05 (n=6, treated vs. untreated control cells), One-way ANOVA followed by Tukey's 
post-hoc tests.  
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its downstream targets in MDA-MB-231 and TR sublines exposed to 1%O2/GF for 6 h, a 
condition known to induce apoptosis as showed in Figure 3-3. Compared to cells with 
intact BHLHE40 activity, MDA-MB-231-BHLHE40-KO and TR-BHLHE40-KD cells 
expressed lower levels of HBEGF mRNA and protein, which was coincident with 
reduced levels of phosphorylation of EGFR, AKT and ERK and increased caspase 9 
cleavage (Figure 3-7A and B). Next, we examined whether active HBEGF peptide could 
rescue MDA-MB-231-BHLHE40-KO cells from apoptosis. As shown in Figure 3-7C, 
addition of HBEGF peptide into culture medium of cells exposed to 1%O2/GF 
significantly reduced activation of caspase 3/7. These observations provide evidence 
supporting a role of HBEGF in promoting cell survival. 
 
Monolayer scratch was found to induce expression of HIF1A, BHLHE40 and 
HBEGF in MDA-MB-231-EV cells (Figure 3-8A), implicating a role of the HIF1A-
BHLHE40-HBEGF axis in cell migration during wound healing. By using the IncuCyte 
ZOOM-ImageLock plate system, we demonstrated that BHLHE40-KO substantially 
diminished the ability of MDA-MB-231 cells to close the wound gaps, which was 
restored by addition of HBEGF peptide (Figure 3-8B and C). In contrast, a HBEGF 
neutralizing antibody [148] inhibited wound healing of LM-EV cells (Figure 3-8B and 
C). To confirm that exosomic HBEGF plays a key role in promoting cell migration, we 
examined the migratory activities of MDA-MB-231 BHLHE40-KO cells in the presence 
of conditioned medium or purified exosomes, which were collected from the MDA-MB-
231 EV cells at 24 h after extensive wound scratch. The Transwell migration assay 
showed that both conditioned medium and purified exosomes from the wounded EV cells 
increased the migratory activity of BHLHE40-KO cells (Figure 3-8D). Together, these 
observations suggest that HBEGF act downstream of BHLHE40 to promote cell 
migration. 
 
To confirm that BHLHE40 and HBEGF are key downstream effectors of HIFs in 
promoting cell migration, we examined the effect of BHLHE40 overexpression on a 
HIF1A/EPAS1 double knockout subline (MDA-MB-231 HIF-dKO). Although HIF1A 
mRNA expression level is approximately 6-fold higher than EPAS1 mRNA in MDA-
MB-231 cells according to reported RNAseq data (GSE73526), compensatory activation 
of EPAS1 could compromise the effect of HIF1A knockout. Therefore, we used HIF-
dKO cells to examine whether BHLHE40 overexpression can rescue molecular and 
phenotypic changes caused by HIF-KO. Gene expression analysis by qPCR showed that 
HIF-dKO reduced baseline and 1%O2/LG induced expression of BHLHE40, HBEGF, 
CTGF and VEGFC mRNAs, which was restored by BHLHE40 overexpression (Figure 
3-9A). In addition, BHLHE40 overexpression reduced cell-cell contact, as showed by cell 
imaging, and increased migratory activity of HIF-dKO cells, as determined by transwell 
assays (Figure 3-9B). Immunoblotting analysis confirmed that BHLHE40 overexpression 
restored expression levels of HBEGF protein in HIF-dKO cells exposed to 1%O2/LG 
(Figure 3-9C). Together, these observations support the notion that BHLHE40 and 
HBEGF act as key downstream effectors of HIFs to promote cell migration. 
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Figure 3-7. BHLHE40 depletion reduced phosphorylation of EGFR, while 
increased Caspase 9 cleavage, in cells exposed to glucose depletion and hypoxia 
(1%O2/GF).  
 
A. BHLHE40 knockout (KO) by CRISPR/Cas9 editing in MDA-MB-231 and BHLHE40 
knockdown (KD) by shRNA in TR cells diminished HBEGF induction by 1% O2/GF 
(6h). mRNA expression levels were determined by qPCR, normalized to RPL13A, and 
presented as mean±SD (n=6). *p<0.05 (n=6, 1%O2/GF vs. control), **p <0.05 (n=6, KO 
vs. EV), One-way ANOVA followed by Tukey's post-hoc tests. B. BHLHE40 depletion 
reduced EGFR activation, as indicated by reduced phosphorylation of EGFR and its 
downstream targets (ERK and AKT), while increasing apoptosis, as indicated by 
detection of cleaved caspase 9. Data from three independent immunoblotting analyses are 
presented. C. HBEGF peptide (10g/ml) reduced apoptosis induced by 1%O2/GF (6h) in 
MDA-MB-231 BHLHE40-KO cells. Apoptosis was determined by Caspase 3/7 assays. 
*p<0.05 (n=6, 1%O2/GF vs. control), **p <0.05 (n=6, HBEGF vs. untreated with 
HBEGF), One-way ANOVA followed by Tukey's post-hoc tests. 
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Figure 3-8. HIF-BHLHE40-HBEGF axis plays a role in promoting cell migration 
during wound healing.  
 
A. Monolayer scratch increased protein levels of HIF1A, BHLHE40 and HBEGF in 
MDA-MB-231 EV cells. Intensive scratch wounds were generated by using the EMD 
Millipore’s Cell Comb scratch assay kit and immunoblotting was performed 6h after cells 
cultured under normoxia (19% O2) or hypoxia (1% O2). B. BHLHE40 knockout (KO) by 
CRISPR/Cas9 editing reduced the migratory activity of MDA-MB-231 cells, which was 
restored by addition of HBEGF peptide into the culture medium. In contrast, a HBEGF 
neutralizing antibody reduced the migratory activity of MDA-MB-231-EV cells. Real-
time assessment of migratory activity after wound scratch was performed by using the 
IncuCyte ZOOM-ImageLock plate system. *P<0.05 (n=6, time points 6-24h, HBEGF vs. 
untreated), **p<0.05 (n=6, time points 6-24h, anti-HBEGF vs. untreated), One-way 
ANOVA followed by Tukey's post-hoc tests. Representative data from two independent 
experiments with 6 replicates are presented. C. Images of representative wound fields at 
0 and 24 h after wound scratch as described in B. D. Conditioned medium or purified 
exosomes from MDA-MB-231-EV cells (24 h after wound scratch) increased migratory 
activities of MDA-MB-231 BHLHE40-KO cells, as determined by the transwells 
migration assays. The migrated cells in six fields were imaged and counted under 
fluorescent microscope. The results were presented as: Percent migration = mean number 
of cells migrating through the uncoated transwells x 100/mean number of seeded cells; 
*p<0.05 (n=12, vs. untreated control), One-way ANOVA followed by Tukey's post-hoc 
tests. 
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Figure 3-9. Effect of BHLHE40 overexpression on molecular and phenotypic 
changes caused by HIF1A/EPAS1 double knockout (HIF-dKO) in MDA-MB-231 
cells.  
 
A. BHLHE40 overexpression restored baseline and hypoxia/low glucose (1% O2/LG (6h) 
induced expression of HBEGF, CTGF, TNFSF12 and VEGFC in in HIF-dKO cells. The 
expression levels of mRNAs were determined by qPCR, normalized to RPL13A and 
presented as mean±SD (n=6). *p<0.05 (n=6, vs. untreated HIF-dKO), **p<0.05 (n=6, vs. 
HIF-dKO exposed to 1% O2/LG for 6h), One-way ANOVA followed by Tukey's post-
hoc tests B. BHLHE40 overexpression decreased cell-cell contact (as showed by the cell 
images) and increased migratory activity of HIF-dKO cells exposed to 1% O2/LG (24h). 
Migratory activity was determined by Transwell assays and presented as meant of 
percentage of migrating cells ± SD (n=6). *p<0.05 (n=6, HIF-dKO vs. control wild-type 
cells), **p<0.05 (n=6, HIF-dKO/BHLHE40 overexpression vs. HIF-dKO), One-way 
ANOVA followed by Tukey's post-hoc tests. C. BHLHE40 overexpression restored 
expression of HBEGF proteins in HIF-dKO cells exposed to 1% O2/GF (6h). Proteins 
were detected by immunoblotting. GAPDH and TBP were used as loading control for 
whole cell extract (WCE) or Nuclear extract (NE), respectively. 
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High expression of BHLHE40 and HBEGF is associated with poor prognosis of 
breast cancer 
 
Having established a role of the BHLHE40-HBEGF axis in enhancing cell 
survival and migration, we sought to examine the association of BHLHE40 and HBEGF 
with clinical characteristics of breast tumors by using the gene expression data in the 
Kaplan Meier plotter database, which contains the Affymetrix microarray expression data 
of 2,178 breast cancer patients [108]. We found that high expression of BHLHE40 or 
HBEGF is significantly associated with shorter interval of relapse free survival (RFS) 
among patients diagnosed with triple-negative breast cancer (TNBC, n=255) and patients 
treated with chemotherapy (n=602) (Figure 3-10). However, BHLHE40 and HBEGF are 
not poor prognostic markers for patients with estrogen receptor positive tumors or 
patients treated with endocrine therapy. In addition, we analyzed the association of 
BHLHE40 and HBEGF with overall survival (OS) of TNBC by using the METABRIC 
dataset in the cBioPortal for Cancer Genomics (Breast Cancer, METABRIC). High 
BHEGF expression was found to be associated with short interval of OS (Figure 3-10C). 
Although TNBC with higher expression of BHLHE40 tends to have a shorter interval of 
OS, this correlation did not reach statistical significance (Figure 3-10C). These findings 
suggest that activation of the BHLHE40-HBEGF pathway contributes to aggressive 
behaviors of TNBC and chemoresistance. 
 
 
Discussion 
 
Breast cancer metastasis is the major cause of fatality in breast cancer patients. 
Adaptation to hypoxia is a driving force of metastatic progression and drug resistance 
[120]. Proteins secreted by tumor cells under hypoxia promote metastasis by altering 
tumor cell behaviors and modifying the tumor microenvironment [119]. Therefore, the 
regulation of hypoxia-driven protein secretion is currently under intense investigation. 
This study, reports a novel role of BHLHE40, a transcription factor directly targeted by 
HIF1A, in regulating exosomic release of HBEGF. Our results suggest that the HIF-
BHLHE40-HBEGF axis constitutes an important signaling mechanism to promote 
metastasis of breast tumors. 
 
Exosomes are 40-100 nm vesicles that originate from the endocytic compartment. 
Exosomes contain a wide range of proteins, lipids, mRNAs and microRNAs (miRNAs) 
that reflect the molecular contents of the parental cells [144]. Compared to normal cells, 
cancer cells exhibit higher activity of exosome secretion, which is further augmented by 
stress conditions, including TP53 activation, alteration of intracellular calcium levels, 
senescence, hypoxia and acidosis [149]. Exosomes released by tumor cells have been 
reported to contain cytokines and growth factors that promote metastasis and 
chemoresistance [149-151]. However, the precise molecular mechanism governing the 
release of exosomes remains elusive. This study however, suggests that BHLHE40 acts 
as a key downstream effector of HIFs to activate transcription and subsequent exosome 
secretion of a set of cytokines and growth factors. 
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Figure 3-10. High expression of BHLHE40 and HBEGF is associated with poor 
prognosis of breast cancer.  
 
A. High expression of BHLHE40 and HBEGF is associated with short interval of relapse 
free survival (RFS) of patients diagnosed with triple-negative breast cancer (TNBC, 
n=255). The gene expression data and patient information were obtained from the 
Kaplan-Meier plotter database. B. High expression of BHLHE40 and HBEGF is 
associated with short interval of RFS among patients treated with chemotherapy (n=602). 
The gene expression data and patient information were obtained from the Kaplan-Meier 
plotter database. C. High expression of HBEGF is associated with short interval of 
overall survival (OS) of patients diagnosed with TNBC (n= 150). The gene expression 
data and patient information were obtained from the cBioPortal for Cancer Genomics 
(Breast Cancer, METABRIC, Nature 2012 & Nat Commun 2016). 
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BHLHE40 was previously described as a transcriptional repressor that binds to 
the class B E-box (CACGTG) and recruits HDAC1 and HDAC2 to block transcription 
[152]. BHLHE40 activation has been linked to cell cycle arrest, senescence, 
differentiation and apoptosis [153-155]. On the other hand, emerging evidence supports a 
role of BHLHE40 in transcription activation and promoting cell survival. For instance, 
BHLHE40 was reported to activate transcription of pro-survival factors in tumor cells, 
including BIRC5 and DeltaNp63 [156, 157]. In addition, BHLHE40 was reported to 
activate the transcription of a panel of cytokines required for activation of murine CD4+ 
T cells [117, 158]. It remains undefined what factors determine the selectivity of 
BHLHE40 to suppress or activate transcription. The BHLHE40-mediated transcription 
activation of DeltaNp63 was shown to depend on its direct interaction with HDAC2 
[156]. In agreement with this observation, our results suggest that BHLHE40 activates 
HBEGF transcription by sequestering HDAC1/2 from DNA binding. It remains to be 
determined whether interfering with HDAC1/2-DNA binding is a general mechanism 
responsible for BHLHE40-mediated transcription activation. 
 
Elevated EGFR activation is known to promote survival, proliferation and 
invasion of tumor cells under hypoxia, and multiple mechanisms have been linked to 
hypoxia-induced EGFR activation [159]. For example, EPAS1 activation by hypoxia was 
shown to increase EGFR mRNA translation [160]. Hypoxia-mediated activation of 
metalloproteases (e.g., ADAM12 and ADAM17) was reported to activate EGFR by 
increasing ectodomain shedding of HBEGF [161, 162]. Our study provides a novel aspect 
of EGFR activation through the BHLHE40-HBEGF axis. In addition to autocrine or 
paracrine effects within tumor cells, exosomic release of HBEGF might exert paracrine 
effect to remodel tumor stroma or endocrine effect to prime distant metastatic niches 
[163].  
 
In conclusion, this study provides evidence supporting an essential role of 
BHLHE40 in exosomic release of HBEGF, a critical pro-survival and pro-metastasis 
factor. The clinical relevance of our findings is evidenced by the fact that the elevated 
expression of BHLHE40 and HBEGF in breast tumors is associated with poor prognosis 
of patients with TNBC and chemoresistance. Therapeutic intervention targeting the 
BHLHE40-HBEGF axis may represent an effective approach to combat hypoxia-driven 
drug resistance and metastasis.  
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CHAPTER 4.    SUMMARY 
 
 
When mammalian cells encounter hypoxia, they develop a variety of mechanisms 
to cope with this stress and survive, as summarized in Table 4-1 [164]. Approximately 1-
1.5% of the genome is transcriptionally responsive to hypoxia. However, there is 
significant heterogeneity in the transcriptional response to hypoxia between different cell 
types [165]. For instance, in the context of tumor cells, HIF1A can impart pro-
tumorigenic abilities by direct upregulation of targets like VEGF, LOX and MMP’s while 
in the context of innate immunity, HIF1A can regulate T cells and lymphocytes to 
promote inflammation by regulating the secretion of cytokines such as CCL5 and IL6 
[166]. Therefore, strategies exploiting hypoxic response for therapy need to take into 
consideration the cell context. This study identifies two HIF1A mediated pathways that 
require the presence of other transcription regulators (i.e., SMARCE1 and BHLHE40) to 
impart pro-metastatic abilities to breast cancer cells. 
 
Low oxygen concentration of solid tumors has been linked to increased migratory 
and invasive potential [19] a pre-requisite to metastatic breast cancer. HIF1A, master 
controller of hypoxia, acts via multiple pathways to bestow on cancer cells pro-survival 
and pro-metastatic abilities [167]. To develop strategies to prevent HIF1A-driven tumor 
progression requires a detailed understanding of upstream regulators and downstream 
effectors of HIF1A signaling pathways. Our results discover two downstream pathways, 
HIF1A/SMARCE1-PTK2 and HIF1A-BHLHE40-HBEGF, that HIF1A exploits to impart 
an increased metastatic potential to the breast cancer cells. Future studies are warranted to 
evaluate the efficacy of strategies targeting HIF1A-SMARCE1 interaction, PTK2 
activation and HBEGF secretion.  
 
 
Key-findings  
 
Key findings of this study are listed below (and represented in Figure 4-1). 
 
• Knockdown of EHMT2, SMARCA4, and KDM6B did not affect the metastatic 
potential of MDA-MB-231 cells. 
 
• SMARCE1 knockdown does not affect the primary tumor growth but 
significantly reduced spontaneous lung metastases in an orthotopic xenograft 
model of breast cancer 
 
• SMARCE1 is required for HIF1A-mediated transactivation of PTK2 in response 
to cell detachment. HIF1A/PTK2 pathway plays a key role in protecting 
circulating tumor cells against anoikis.  
 
• BHLHE40 knockdown reduced both primary tumor burden and spontaneous lung 
metastasis in-vivo 
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Table 4-1. Summary of epigenetic factors involved in hypoxia-regulated gene 
expression. 
 
Category 
Chromatin 
modifiers 
involved 
Genes or proteins 
regulated 
Phenotypic changes 
Transcriptional co-
regulators 
CITED1, 
HDAC, PCAF, 
PPARGC1A, 
PKM2, MCM, 
FHL 
Various hypoxia-
responsive genes, TP53, 
HIF1A, BID, VEGF, 
LDHA, PDK1, 
SLC2A1, HK1 
Angiogenesis, cell 
cycle progression, 
glycolytic pathway, 
cell proliferation, and 
other processes 
regulated by hypoxia 
Chromatin-
modifying 
complexes 
SWI/SNF, 
SMARCA4, 
ISWI, MTA1 
HIF1A, SHBG, ITIH, 
HIF1AN, BNIP3, CA9, 
VEGF 
Cell cycle arrest, 
hematopoietic and 
vascular development, 
apoptosis, angiogenesis 
Chromatin 
modifiers 
mediating hypoxia-
induced EMT 
HDAC3, 
WDR5 
EMT marker genes 
(CDH1, JUP, CDH2, 
VIM, etc.) 
Migration, invasion, 
metastasis 
 
Hypoxia activated transcriptional co-regulators, chromatin modifying complexes, histone 
modification enzymes and their role in tumor progression. Reprinted with permission 
from Kou-Juey Wu, Epigenetic Regulation of hypoxia responsive gene expression: 
Focusing on chromatin and DNA modifications. International Journal of Cancer, 2013, 
Volume 134, Issue2. 
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Figure 4-1. Summary of results.  
 
A. HIF1A modulates chromatin remodeling via the SMARCE1 subunit of the SWI/SNF 
complex and the circadian cycle by direct transcriptional regulation of BHLHE40 leading 
to tumor progression and metastasis. B. SMARCE1 regulates metastatic potential of 
breast cancer cells by promoting survival of detached cells through the HIF1A/PTK2 
pathway. C. HIF1A-BHLHE40 driven HBEGF activation potentates breast cancer cell 
survival, invasion and metastasis. 
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• BHLHE40 functions as key downstream effector of HIF1A to regulate exosomal 
secretion of HBEGF, which plays a key role in supporting cell migration and 
survival.   
 
 
SMARCE1: Implications in Other Cancers and Further Direction 
 
Chromatin remodelers have been shown to play a role in tumor progression [167]. 
One of these important chromatin remodelers is the SWI/SNF nucleosome remodeling 
complex also implicated in co-activation of HIF1A target genes [48]. SMARCE1/BAF57 
is one of the subunits of this complex. Germline mutation in SMARCE1 predispose 
young patients to both spinal and intracranial clear cell meningiomas (CCM) and studies 
reveal heterozygous loss of function mutation in SMARCE1 to be causative of this tumor 
[168]. This study warrants genetic sequencing of future cases of childhood CCM 
including investigation of SMARCE1 gene [169] and such mutation screening can help 
facilitate meningioma classification [170]. SMARCE1 also plays a role in regulating drug 
response and cytokine secretion of ovarian cancer cells. siRNA mediated knockdown of 
SMARCE1 was reported to increase cell cycle arrest in G1 when cells were treated with 
anticancer drugs such as cisplatin, doxorubicin, paclitaxel and 5-fluorouracil [171]. 
Overexpression of SMARCE1 in SKOV3 ovarian cancer cells resulted in secretion of 
IL8, MIP1B and RANTES chemokines, which are associated with CD8+ cytotoxic T-cell 
infiltration. In addition, SMARCE1 has been shown to be a novel target to abrogate 
androgen receptor-mediated gene activation in prostate cancer [172] [173].  
 
Our study reveals a novel link of SMARCE1 to HIF1A-mediated breast cancer 
metastasis. PTK2, a non-receptor tyrosine kinase is activated by integrin engagement and 
growth factor stimulation. Following phosphorylation, PTK2 activates MAPK and AKT 
pro-survival pathways [174]. PTK2 gene amplification has been reported in various 
cancers and has been shown to aid in cancer initiation and cell survival. Recently, PTK2 
activation has been shown to be required for Src-regulated CDH1 expression in colon 
cancer cells and inhibition of PTK2 activity reduced cell invasion in these cells. In 
addition, PTK2 overexpression can modulate ITGB1 to enhance EMT, invasion, and 
metastasis of cancer cells to the lung [175]. Blocking PTK2 activation has been proven to 
impair the migratory potential of breast cancer cells [176]. In this study, we identified a 
novel mechanism of activation of PTK2 by HIF1A/SMARCE1 in breast cancer cell, 
which contributes to HIF1A-mediated anoikis resistance.  
 
Further studies are needed to identify other crucial SMARCE1 targets to facilitate 
the development of SMARCE1-targeted therapy. Additional research should focus on 
identifying other SWI/SNF accessory subunits involved in the hypoxic response and 
delineate which domains of SMARCE1 are involved in HIF1A interaction.  
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BHLHE40: Implications in Other Cancers and Further Direction 
 
Deregulation of BHLHE40/DEC1 has been implicated in various types of 
malignant carcinomas [177]. In human glioblastomas, BHLHE40 facilitates the metabolic 
adaptability of cells to hypoxia stress by increasing glycolysis [178]. BHLHE40 
expression is a poor prognostic marker in pancreatic cancer and modulates chemo 
sensitivity to gemcitabine [179]. BHLHE40 was reported to be activated by TGFB in 
colorectal cancer cells to invoke anti-apoptotic response by blocking the apoptotic 
pathways initiated by mitochondria [180] [181]. Dominant negative mutants of 
BHLHE40 were shown to prevent lung and liver metastasis of mammary carcinoma cell 
lines JygMC(A) and 4T1 [182]. In pancreatic cancer, BHLHE40 activation by TGFB has 
been shown to regulate EMT by regulating the expression of SMAD3, SNAIL, Caludin-
4, and N-cadherin [133]. Studies in human endometrial cancer cells, however, show that 
BHLHE40 and BHLHE41 act to block EMT by suppressing TWIST1 expression through 
competing with SP1 binding to DNA [183]. In addition, BHLHE40 has also been 
implicated in regulation of cytokine secretion [71], and it plays a key role in production 
of GM-CSF and IL-10 in T-cells [184]. Our results show that BHLHE40 is required for 
exosomal secretion of HBEGF in response to HIF1A activation in breast cancer cells. 
HBEGF, a ligand of EGFR, which plays a key role in promoting breast cancer cell 
survival and migration [185]. 
 
Epidermal growth factor receptor belongs to a family of receptor tyrosine kinase 
that is anchored in the cytoplasmic membrane and is activated by several ligands like 
epidermal growth factor (EGF), TGFB, amphiregulin, and HBEGF. Upon activation, 
EGFR causes activation of the MAPK/ ERK, AKT/PI3K, JNK, STAT’s and E2F family 
of proteins that impart pro-survival capabilities to tumor cells. EGFR/MAPK/AKT 
pathways have been often dysregulated in human cancers [186]. EGFR is overexpressed 
in 50% of triple negative breast cancers (TNBC’s) and EGFR targeted therapies are being 
used to enhance the initial sensitivity of TNBC cells to cytotoxic therapy [187]. Co-
treatment of EGFR pathway inhibitors with PI3K/AKT pathway inhibitors enhanced the 
anti-proliferative effects of EGFR inhibitors in MDA-MB-468 cells. Combinational 
therapy of gefitinib and PI-103 reduced phosphorylation of AKT and MAPK and induced 
caspase-dependent apoptosis in basal like breast cancer cells [188]. Recent studies have 
also shown that EGFR signaling can enhance tumor invasion by upregulating MMP-9 
expression and PTK2 phosphorylation in MDA-MB-231 and MCF-7 cells [189]. These 
observations show the importance of EGFR activation in several steps of the metastatic 
cascade [190-192]. 
 
While this study has produced some valuable insights into the role of BHLHE40 
in cytokine release induced by HIF1A activation, there are two unanswered questions that 
need to be addressed. First, the molecular mechanism underlying BHLHE40-mediated 
transcription activation of HBEGF. Second, whether BHLHE40 plays a role in regulating 
exosome assembly, transport and cargo loading. Probing for answers to these two 
questions will facilitate investigation in the therapeutic potential of BHLHE40/HBEGF 
pathway. 
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